Liver disorder
MONDO:0005154A disease involving the liver.
Also known as: disease of liver, disease or disorder of liver, disorder of liver, hepatic disease, hepatic disorder, liver and intrahepatic bile duct disorder, liver disease, liver disease or disorder
3604 clinical trials for this condition and its sub-types, 323 tagged with Liver disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Liver disorder
-
Liver and intrahepatic bile duct neoplasm 77 trials · 1,743 incl. sub-types
17 sub-types
- Liver cancer 254 trials · 1,700 incl. sub-types Sub-types →
- Biliary tract neoplasm 31 trials · 623 incl. sub-types Sub-types →
- Liver hemangioma 6 trials Sub-types →
- Undifferentiated embryonal sarcoma of the liver 6 trials
- Hepatocellular adenoma 2 trials Sub-types →
- Fibrohistiocytic inflammatory pseudotumor of the liver 0 trials
- Hepatic angiomyolipoma 0 trials
- Hepatic granuloma 0 trials
- Inflammatory pseudotumor of the liver 0 trials
- Liver adenomatosis 0 trials
- Liver inflammatory myofibroblastic tumor 0 trials
- Liver leiomyoma 0 trials Sub-types →
- Liver lipoma 0 trials Sub-types →
- Liver mesenchymal hamartoma 0 trials
- Liver solitary fibrous tumor 0 trials
- Lymphoplasmacytic inflammatory pseudotumor of the liver 0 trials
- Solitary necrotic nodule of the liver 0 trials
-
Hepatitis 50 trials · 731 incl. sub-types
9 sub-types
- Viral hepatitis 12 trials · 443 incl. sub-types Sub-types →
- Metabolic dysfunction-associated steatohepatitis 231 trials
- Alcoholic hepatitis 31 trials
- Autoimmune hepatitis 30 trials · 31 incl. sub-types Sub-types →
- Drug-induced hepatitis 3 trials
- Fulminant viral hepatitis 3 trials
- Granulomatous hepatitis 0 trials
- Hepatic tuberculosis 0 trials
- Idiopathic peliosis hepatis 0 trials
-
Fatty liver disease 154 trials · 616 incl. sub-types
4 sub-types
- Metabolic dysfunction-associated steatotic liver disease 508 trials · 572 incl. sub-types Sub-types →
- Alcoholic fatty liver disease 14 trials
- Metabolic dysfunction and alcohol associated liver disease 8 trials
- Visceral steatosis, congenital 5 trials
-
Cirrhosis of liver 519 trials · 597 incl. sub-types
3 sub-types
- Cirrhosis, familial 4 trials · 79 incl. sub-types Sub-types →
- Alcoholic liver cirrhosis 18 trials
- Hepatitis C induced liver cirrhosis 5 trials
-
Liver failure 71 trials · 197 incl. sub-types
3 sub-types
- Chronic liver failure 124 trials
- Acute liver failure 16 trials Sub-types →
- Infantile liver failure 0 trials · 1 incl. sub-types Sub-types →
-
Hepatic vascular disorder 1 trial · 116 incl. sub-types
11 sub-types
- Portal hypertension 90 trials
- Portal vein thrombosis 18 trials
- Hepatic veno-occlusive disease 6 trials Sub-types →
- Fontan-associated liver disease 5 trials
- Portosinusoidal vascular disease 3 trials Sub-types →
- Budd-Chiari syndrome 1 trial
- Nutmeg liver 1 trial
- Hepatic infarction 0 trials
- Hepatic vein thrombosis 0 trials
- Liver angiosarcoma 0 trials
- Peliosis hepatis 0 trials
-
Fibrotic liver disease 96 trials
-
Alcoholic liver disease 44 trials · 85 incl. sub-types
3 sub-types
- Alcoholic hepatitis 31 trials
- Alcoholic liver cirrhosis 18 trials
- Alcoholic fatty liver disease 14 trials
-
Drug-induced liver injury 21 trials · 23 incl. sub-types
1 sub-type
- Drug-induced hepatitis 3 trials
-
Hepatic porphyria 4 trials · 23 incl. sub-types
7 sub-types
- Erythropoietic protoporphyria 15 trials Sub-types →
- HMBS-related hepatic porphyria 0 trials · 5 incl. sub-types Sub-types →
- Hereditary coproporphyria 5 trials
- PPOX-related hepatic porphyria 0 trials · 2 incl. sub-types Sub-types →
- Porphyria cutanea tarda 0 trials · 1 incl. sub-types Sub-types →
- Hepatic cutaneous porphyria 0 trials
- Porphyria due to ALA dehydratase deficiency 0 trials
-
Familial intrahepatic cholestasis 1 trial · 17 incl. sub-types
4 sub-types
- Progressive familial intrahepatic cholestasis 16 trials · 17 incl. sub-types Sub-types →
- Benign recurrent intrahepatic cholestasis 2 trials · 5 incl. sub-types Sub-types →
- Cholestasis, intrahepatic, of pregnancy, 1 0 trials
- Cholestasis, intrahepatic, of pregnancy, 3 0 trials
-
Hepatorenal syndrome 13 trials
-
Bile duct cyst 10 trials
-
Liver abscess (disease) 4 trials
-
5 sub-types
-
Glycogen storage disease due to liver phosphorylase kinase deficiency 0 trials · 2 incl. sub-types
2 sub-types
- Glycogen storage disease IXa1 2 trials
- Glycogen storage disease IXc 2 trials
-
Aagenaes syndrome 1 trial
-
Hepatoportal sclerosis 0 trials
-
Hepatopulmonary syndrome 0 trials
-
Hyperbiliverdinemia 0 trials
-
Liver disease, severe congenital 0 trials
-
Polycystic echinococcosis 0 trials
-
Primitive portal vein thrombosis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 648 trials in this tab.
-
One shot, six protections: could a single vaccine replace multiple infant shots?
Vaccine OngoingThis trial tests a new vaccine called LBVD, which combines protection against six diseases: diphtheria, tetanus, whooping cough, hepatitis B, polio, and Hib. The study enrolls healthy infants around 6 to 8 weeks old who receive three doses at 6, 10, and 14 weeks of age. Researche…
Phase 2/3 • Sponsor: LG Chem • Aim: Vaccine
Last updated Sep 05, 2026 00:00 UTC
-
Booster shot hope: extra hepatitis a vaccine studied for thai kids
Vaccine OngoingThis study looks at whether a second, inactivated hepatitis A vaccine can safely boost protection in healthy Thai children and teens who did not develop enough antibodies after a single dose of a live-attenuated hepatitis A vaccine. About 36 participants who took part in an earli…
Phase 3 • Sponsor: Chiang Mai University • Aim: Vaccine
Last updated Jun 27, 2026 12:37 UTC
-
New vaccine aims to train immune system against hepatitis b
Vaccine OngoingThis early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works again…
Phase 1 • Sponsor: AstriVax Therapeutics • Aim: Vaccine
Last updated Jun 27, 2026 12:10 UTC
-
New hope for NASH: drug targets liver scarring in advanced disease
Disease control OngoingThis study tests an experimental drug, GSK4532990, in 284 adults with nonalcoholic steatohepatitis (NASH) and advanced liver scarring. The goal is to see if the drug can improve liver fibrosis and inflammation compared to a placebo over 52 weeks. Participants must have a liver bi…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Device aims to keep donor livers healthier for transplant
Disease control By invitation onlyResearchers are collecting data on how well donor livers preserved with the LIVERguard device function after transplantation. The study includes liver transplant recipients whose donor organs were stored in the device, as well as a comparison group of patients who received livers…
Sponsor: Paragonix Technologies • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation boosts liver size, paving way for cancer surgery
Disease control OngoingThis study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…
Sponsor: Northwestern University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Stem cells for failing livers: does the delivery route matter?
Disease control OngoingResearchers are testing whether human umbilical cord mesenchymal stem cells can help people with end-stage liver disease, and whether the route of delivery changes the outcome. Participants receive the cells either through a peripheral vein or through the hepatic artery. The tria…
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control PausedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a vaccine tame chronic hepatitis b?
Disease control OngoingThis early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …
Phase 1/2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…
Phase 1/2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Tiny trial tests Radiation-Immunotherapy cocktail for tough bile duct cancer
Disease control OngoingThis early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immunotherapy combo shows promise for advanced liver cancer
Disease control OngoingThis study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for kids with liver cancer: international trial tests smarter chemo combos
Disease control OngoingThis study tests different combinations of chemotherapy drugs, along with surgery, for children and young adults with two types of liver cancer: hepatoblastoma and hepatocellular carcinoma. The goal is to see which combinations work best to stop tumor growth and improve survival.…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo before liver surgery shows promise in early trial
Disease control OngoingThis phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug cocktail aims to boost liver cancer fight
Disease control CancelledThis pilot study tests whether adding the immunotherapy drugs cemiplimab (with or without fianlimab) after a standard liver cancer procedure called Y90 radioembolization can help control hepatocellular carcinoma. About 20 adults with liver cancer will be randomly assigned to one …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Does the clock matter? trial tests endoscopy timing for cirrhosis bleeding
Disease control OngoingPeople with liver cirrhosis can develop dangerous bleeding from swollen veins in the esophagus or stomach. Doctors use endoscopy to find and treat the bleeding, but they do not know the best time to do it. This trial randomly assigns patients to different endoscopy timings to see…
Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combos tested to improve lymphoma control in younger patients
Disease control OngoingThis study tests three different chemotherapy combinations in people aged 70 or younger with newly diagnosed mantle cell lymphoma, a type of blood cancer. The goal is to see if adding a targeted drug called acalabrutinib to standard chemo improves how well the cancer responds. Ar…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
DNA vaccine trial aims to train immune system against hepatitis c
Disease control OngoingThis early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hepatitis b drug shows promise in Mid-Stage trial
Disease control OngoingThis Phase 2 study tests an experimental drug called ALG-000184 against a standard hepatitis B medication (tenofovir) in 200 adults with chronic hepatitis B. Participants take one pill daily for 48 weeks. The main goal is to see if the new drug can lower hepatitis B virus levels …
Phase 2 • Sponsor: Aligos Therapeutics • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo aims to tame chronic hepatitis b
Disease control OngoingThis Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog drugs can better control chronic hepatitis B. About 116 adults with the infection will receive either the combination or a placebo plus standard drugs. The main goal is to see if the combinatio…
Phase 2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can exercise melt away liver fat?
Disease control By invitation onlyResearchers are testing whether aerobic exercise, resistance exercise, or a combination of both can reduce liver fat in adults with metabolic dysfunction-associated steatotic liver disease. The trial enrolls 186 people aged 18 to 45 with a body mass index between 25 and 40 and ev…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can tailoring bypass length improve weight loss surgery results?
Disease control By invitation onlyResearchers are studying how the length of bypassed intestine during gastric bypass affects weight loss, complications, and metabolic changes in people with severe obesity. Participants will have different lengths of intestine bypassed and will provide blood and stool samples bef…
Sponsor: University of Missouri-Columbia • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Ketogenic diet vs mediterranean diet: which better reshapes metabolism?
Disease control OngoingResearchers compare a very low calorie ketogenic diet with a Mediterranean-style low-calorie diet in 40 adults who have type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Participants follow one of the two diets for several weeks. The study measures changes in weigh…
Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug bitopertin offers hope for sunlight pain relief in rare blood disorders
Disease control By invitation onlyThis long-term study tests the safety and effectiveness of bitopertin (DISC-1459) in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain from sunlight exposure. About 230 participants who previously took bitoper…
Phase 2/3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a liver drug also protect the heart? study tests ursodeoxycholic acid in fatty liver disease
Disease control OngoingResearchers at a Prague hospital are observing whether ursodeoxycholic acid, a drug used for certain liver conditions, affects liver fat, liver enzymes, and markers of heart and blood vessel health in people with non-alcoholic fatty liver disease. The study includes 20 adults who…
Sponsor: General University Hospital, Prague • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New oral drug shows promise for rare sun allergy conditions
Disease control OngoingThis study is for people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP), rare conditions that cause severe pain and skin reactions to sunlight. The purpose is to check the long-term safety of an oral medication called dersimelagon. About 301 participant…
Phase 3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Triple therapy under the microscope: does it transform cystic fibrosis care?
Disease control OngoingResearchers are observing how elexacaftor/tezacaftor/ivacaftor triple combination therapy affects people with cystic fibrosis in routine care. The study follows two groups: children aged 6 to 11 and people aged 12 and older. Over seven years, they measure lung function, inflammat…
Phase 4 • Sponsor: Royal College of Surgeons, Ireland • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cocktail of drugs and procedure shows promise for liver cancer
Disease control OngoingThis study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control PausedThis trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Diabetes drug semaglutide tested as potential treatment for fatty liver disease NASH
Disease control OngoingThis study tests whether semaglutide, a medicine already used for type 2 diabetes, can help people with NASH, a serious liver condition. About 1205 adults with NASH and liver scarring (stage 2 or 3) will receive weekly injections of semaglutide or a placebo for up to 5 years. The…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Text alerts could save transplanted organs in young patients
Disease control OngoingThis study tests whether text message reminders and a smart pillbox can help teenagers and young adults take their daily anti-rejection medicine on time after a kidney or liver transplant. About 65 participants aged 13-25 will use an electronic pillbox that tracks when they take …
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for advanced liver cancer: immunotherapy cocktails under study
Disease control OngoingThis clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for advanced tumors: drug trial targets untreated patients
Disease control OngoingThis study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill could let Sun-Sensitive patients enjoy the outdoors
Disease control OngoingThis Phase 3 trial tests whether bitopertin, a daily pill, can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will take bitopertin or a placebo for 6 months. …
Phase 3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat bile duct cancer
Disease control OngoingThis study tests whether adding the experimental drug CTX-009 to standard chemotherapy (paclitaxel) helps adults with advanced bile duct, gallbladder, or ampullary cancer that has worsened after one prior treatment. About 168 participants will be randomly assigned to receive eith…
Phase 2/3 • Sponsor: Compass Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThis study tests a new drug called elafibranor in people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants either did not get enough help from or could not take the standard medicine. The goal is to see if elafi…
Phase 3 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for liver disease: drug shows promise in reducing damage
Disease control OngoingThis study tests a daily pill called elafibranor in about 18 Japanese adults with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. Participants had not responded well to standard treatment. The main goal is to see if the drug im…
Phase 3 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a diabetes drug shrink fatty liver in thyroid patients?
Disease control OngoingThis trial tests whether dapagliflozin, a drug used for diabetes, can reduce liver fat in people with underactive thyroid (hypothyroidism) who also have non-alcoholic fatty liver disease (NAFLD). Half of the 50 participants will take dapagliflozin daily, and the other half will t…
Early phase 1 • Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New obesity drug combo enters early human testing
Disease control OngoingThis study tests a new drug combination (AZD9550 and AZD6234) for weight loss in 166 adults who are overweight or obese, with or without type 2 diabetes. The main goals are to check safety, tolerability, and how the drug moves through the body. It is an early-stage trial, so it f…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New combo therapy targets liver cancer in clinical trial
Disease control OngoingThis study tests a two-step treatment for liver cancer. First, patients receive TheraSphere, tiny radioactive beads injected into the liver to target tumors. Then, they get two immunotherapy drugs (durvalumab and tremelimumab) to help the immune system fight remaining cancer cell…
Phase 2 • Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a gut bug help heal fatty liver? new trial begins
Disease control OngoingThis early-stage trial is testing whether a pasteurized gut bacterium called Akkermansia muciniphila can help people with metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition. About 40 adults will take either a low, medium, or high dose…
Phase 1 • Sponsor: Leeuwenhoek Laboratories Co. Ltd. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immunotherapy combo shows promise in bile duct cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancer live longer. About 810 participants received either durvalumab or a placebo alongside chemo. The study m…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Liver cancer hope: new combo tested after standard treatment fails
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard targeted therapy (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes about 557 adults whose cancer worsened after initial treatment with atezolizumab and bevaciz…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with MTAP deletion
Disease control OngoingThis early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a simple protein infusion boost brain function in liver disease?
Disease control OngoingThis study looks at whether giving a protein called albumin through a vein can help improve thinking and memory in people with liver cirrhosis who have had episodes of confusion (hepatic encephalopathy). The trial will involve 30 participants who will receive both albumin and a p…
Phase 2 • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink inoperable bile duct tumors?
Disease control OngoingThis phase II trial is testing whether a combination of three treatments—QL1706 (an immunotherapy), lenvatinib (a targeted therapy), and GEMOX (two chemotherapy drugs)—can help people with bile duct or gallbladder cancer that cannot be removed by surgery. The study will enroll ab…
Phase 2 • Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Could a poop pill curb alcohol cravings in liver disease patients?
Disease control OngoingThis study tests whether capsules containing bacteria from healthy people can safely reduce alcohol cravings and drinking in adults with alcohol-related liver disease and cirrhosis. About 80 participants will receive either the bacteria capsules or a placebo, and researchers will…
Phase 1/2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat liver cancers
Disease control OngoingThis phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for young cancer patients: drug duo targets tough tumors
Disease control PausedThis study tests a new drug called DT2216 combined with the chemotherapy irinotecan in children, teens, and young adults whose solid tumors have come back or not responded to treatment. The goal is to find the safest dose and see if the combination can shrink tumors, especially i…
Phase 1/2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells aim to calm liver scarring in first human trial
Disease control OngoingThis study tests a new treatment called RTX001 for people with severe liver scarring (cirrhosis) that has led to complications. RTX001 uses the patient's own immune cells, modified in a lab to reduce inflammation and scarring. The trial will enroll 30 adults to check if the thera…
Phase 1/2 • Sponsor: Resolution Therapeutics Limited • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Experimental combo aims to rally immune system against tough liver cancer
Disease control OngoingThis early-phase trial tests whether adding an immune-boosting drug called IRX-2 to standard immunotherapy (nivolumab) and a low dose of chemotherapy (cyclophosphamide) is safe and tolerable for people with advanced liver cancer that has come back or spread. Only 8 participants a…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Which stent lasts longest? a Head-to-Head test for bile duct blockage
Disease control OngoingThis trial is testing three types of metal stents used to relieve jaundice in people with advanced cancer blocking the bile duct. The stents – uncovered, partially covered, or fully covered – are placed during an endoscopic procedure to keep the duct open. The study will compare …
Sponsor: Region Stockholm • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Engineered immune cells take on liver cancer in new trial
Disease control OngoingThis study tests a therapy called AZD5851, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack liver cancer cells. The trial includes 94 adults with advanced or recurrent liver cancer that has not responded to standard treatments. …
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Cancer patients to continue promising treatments in major extension trial
Disease control By invitation onlyThis long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Could a vending Machine-Style kiosk curb HIV and overdose deaths in rural america?
Disease control OngoingThis study is testing a special kiosk placed in rural Appalachian Kentucky that provides clean syringes and harm reduction supplies to people who inject drugs. The goal is to see if the kiosk helps reduce the spread of HIV and hepatitis C, and lowers the risk of drug overdose. Ab…
Sponsor: April M Young • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug aims to reverse liver damage from heavy drinking
Disease control OngoingThis study tests a weekly injection called pemvidutide in 100 adults with alcohol-related liver disease. Participants are overweight or obese and have a history of heavy drinking. The goal is to see if the drug can reduce liver stiffness and scarring over 24 to 48 weeks compared …
Phase 2 • Sponsor: Altimmune, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart advanced liver cancer?
Disease control OngoingThis early-stage trial is testing whether combining two investigational drugs, livmoniplimab and budigalimab, can safely help people with advanced liver cancer (hepatocellular carcinoma) that has worsened after initial treatment. The study involves about 20 adults in China with a…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo aims to stop liver Cancer's return in High-Risk patients
Disease control OngoingThis study tests whether the drugs durvalumab (alone or with bevacizumab) can delay or prevent liver cancer from returning in patients who have had surgery or ablation to remove their tumors. About 900 participants at high risk of recurrence will receive either the drug(s) or a p…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
One-Day liver cancer treatment could cut hospital time in half
Disease control OngoingThis study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a phone app beat fatty liver? new trial tests digital coaching
Disease control OngoingThis trial tests whether a smartphone app and remote diet/exercise coaching can help people with non-alcoholic fatty liver disease lose weight and reduce liver fat. 120 participants will either get standard lifestyle advice or use the app with daily meal tracking, weekly recipe a…
Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can calming the immune system save Kids' livers?
Disease control OngoingThis study tests whether two drugs that calm the immune system—high-dose steroids or anti-thymocyte globulin—can help children with sudden, severe liver failure survive without needing a liver transplant. About 163 children aged 1 to 17 will be randomly assigned to receive one of…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can an immunotherapy drug keep liver cancer at bay after surgery?
Disease control OngoingThis trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…
Phase 2/3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Could estrogen patch reverse liver damage in postmenopausal women?
Disease control OngoingThis trial tests whether an estradiol patch can reduce liver fat and scarring in postmenopausal women with NASH, a progressive form of fatty liver disease. The study enrolls women aged 45-70 with NASH or fatty liver, giving them either a daily estradiol patch or a placebo for a p…
Phase 3 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo therapy shows promise for tough bile duct cancer
Disease control OngoingThis Phase 2 trial is testing a combination of paclitaxel polymer micelle and immunotherapy for people with advanced biliary tract cancer whose disease has progressed after standard first-line treatment. The study aims to see if this new drug combo can shrink tumors and control t…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Four-Drug cocktail tame inoperable liver cancer?
Disease control OngoingThis trial is testing whether a combination of chemotherapy, immunotherapy, and a targeted therapy can help people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be removed with surgery. Participants receive a regimen of two chemotherapy drugs (oxa…
Early phase 1 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New device aims to improve liver transplant outcomes
Disease control OngoingThis study gives continued access to a device that preserves donated livers before transplant. It includes 120 adults on the transplant waiting list. The goal is to collect safety data and check for early signs of liver problems after surgery.
Sponsor: Organ Recovery Systems, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for rare bile duct cancer: targeted pill shows promise in Late-Stage trial
Disease control OngoingThis study tests a daily pill called ivosidenib in 220 adults with advanced bile duct cancer that has a specific IDH1 gene mutation and has not responded to prior treatment. The goal is to confirm the drug's safety and effectiveness. Participants take the tablet once daily in 28-…
Phase 3 • Sponsor: Servier Affaires Médicales • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can two radiation therapies team up to fight liver cancer?
Disease control OngoingThis trial is testing whether combining two types of radiation therapy can safely treat liver cancer that cannot be removed with surgery. The approach uses Y-90 microspheres delivered directly to the liver, followed by targeted external radiation (SBRT). The study also uses PET-C…
Phase 1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can an immune booster keep liver cancer away?
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug nivolumab can prevent liver cancer from coming back in people who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. The…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New flavored chemo drink aims to ease treatment for kids with hard-to-treat cancers
Disease control OngoingThis early-phase study tests a flavored, drinkable version of the chemotherapy drug irinotecan (VAL-413) combined with another drug (temozolomide) in children and young adults up to age 30 whose solid tumors have come back. The main goal is to find the safest dose and see how the…
Phase 1 • Sponsor: Valent Technologies, LLC • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can Pre-Surgery drug cocktail stop liver cancer from coming back?
Disease control OngoingThis trial is testing whether giving a combination of drugs before surgery can reduce the risk of liver cancer returning in patients with a single, early-stage tumor that has a high chance of recurrence. Participants will receive either chemotherapy directly into the liver or a t…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a common cholesterol drug help manage a rare liver disease?
Disease control OngoingThis trial is testing the long-term safety of fenofibrate, a drug usually used for high cholesterol, in people with primary biliary cholangitis (PBC), a rare liver disease. The study involves 15 adults who have already completed a previous fenofibrate trial for PBC. Researchers a…
Early phase 1 • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo therapy shows promise for bile duct cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with advanced biliary tract cancer (a type of bile duct cancer). About 142 participants will receive the combination, and researchers will track side effects, s…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Freeze-and-Immune combo takes on tough liver cancer
Disease control OngoingThis early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive t…
Phase 1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase 2/3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New immunotherapy combo aims to fight advanced liver cancer
Disease control OngoingThis Phase 3 study tests whether combining two immunotherapy drugs, durvalumab and tremelimumab, helps people with advanced liver cancer live longer than the current standard drug sorafenib. About 1,300 participants who have not had prior systemic therapy are being enrolled. The …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a cancer vaccine prime the body to better fight liver tumors?
Disease control OngoingThis trial tests whether giving a personalized dendritic cell vaccine before a standard liver-directed therapy (TACE) can improve outcomes for people with advanced liver cancer that has not responded to other treatments. The vaccine is made from the patient's own immune cells and…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a bile acid blocker ease severe itching in a rare liver disease?
Disease control Expanded access (ended)This expanded access program offers the experimental drug odevixibat to people with progressive familial intrahepatic cholestasis (PFIC) who have severe itching and high bile acid levels but cannot join the main clinical trial. The drug works by blocking a bile acid transporter i…
Sponsor: Albireo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a menopause-mimicking drug fight fatty liver in endometriosis patients?
Disease control OngoingThis study tests whether goserelin acetate, a drug that temporarily stops menstruation (like a short-term menopause), can reduce liver fat in women with endometriosis who also have fatty liver disease. Researchers will measure liver fat and stiffness using ultrasound in 62 women …
Phase 4 • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New targeted pill takes on Hard-to-Treat cancers with IDH mutations
Disease control OngoingThis early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
Disease control OngoingThis phase 2 trial is testing whether adding either ramucirumab (a blood-vessel blocker) or merestinib (a cell-signal blocker) to standard chemotherapy (cisplatin + gemcitabine) can help people with advanced or metastatic biliary tract cancer live longer without their disease wor…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a new drug ST316 shrink Hard-to-Treat tumors?
Disease control OngoingThis trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…
Phase 1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Cow's first milk could be a lifeline for severe Alcohol-Related hepatitis
Disease control OngoingThis phase 3 trial investigates whether bovine colostrum—the nutrient-rich first milk from cows—can improve survival in people with severe alcohol-associated hepatitis. The condition involves liver inflammation, a leaky gut, and a high risk of infection. Participants receive eith…
Phase 3 • Sponsor: Dayanand Medical College and Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control By invitation onlyThis study investigates whether tirzepatide, a drug used for diabetes and weight loss, can reverse biological aging in people with HIV who are virally suppressed and have obesity. Participants receive tirzepatide for 25 weeks after a diet program. Researchers measure epigenetic a…
Phase 4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immune cell therapy takes on untreatable liver cancer
Disease control OngoingThis study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). …
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a diabetes drug reverse liver scarring?
Disease control OngoingThis study tests whether semaglutide, a drug already used for obesity and type 2 diabetes, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD). Participants are adults aged 40 to 80 who are overweight or have type 2 diabetes. The trial will also val…
Phase 2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New targeted therapy aims at Hard-to-Treat bile duct cancers
Disease control OngoingThis phase 2 trial tests an experimental drug called SHR-A1811 in people with advanced biliary tract cancer that has HER2 expression or amplification and has stopped responding to earlier treatments. The drug is an antibody-drug conjugate designed to deliver a chemotherapy-like p…
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Texts and tools could help liver transplant patients stay on track
Disease control OngoingThis study tests whether technology and caregiver support can help liver transplant recipients take their medications correctly. Researchers will enroll 360 adults who received a liver transplant within the past 3 months. Participants will use a system called Way to Health, which…
Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug cocktail aims to stall liver cancer that Can't be cut out
Disease control OngoingThis phase 3 trial tests whether adding two drugs (durvalumab and bevacizumab) to a standard liver cancer procedure called TACE can help control the disease longer. About 724 patients with liver cancer that cannot be surgically removed are participating. The main goal is to see h…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug cocktail shows promise in liver cancer fight
Disease control OngoingThis study tests whether adding three drugs (durvalumab, tremelimumab, and lenvatinib) to a standard liver cancer procedure called TACE can help people with liver cancer that cannot be removed by surgery. About 760 participants worldwide will receive either TACE alone or TACE plu…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a common diabetes drug help heal fatty liver?
Disease control CancelledThis study looks at whether a GLP-1 receptor agonist, a drug already used for diabetes and obesity, can improve fat buildup in the liver and blood in people with MASLD. Researchers will measure changes in fats, proteins, and genes in 30 participants who already take the drug. The…
Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
Disease control OngoingThis phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…
Phase 1 • Sponsor: University Hospital, Ghent • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for liver cancer patients with cirrhosis: safety trial launches
Disease control OngoingThis study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple Hard-to-Treat cancers
Disease control CancelledThis study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug aims to clear hepatitis b in HIV patients
Disease control OngoingThis study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to stop liver failure in NASH patients
Disease control OngoingThis phase 3 study tests whether a daily pill called resmetirom can prevent serious liver events like liver failure, need for transplant, or bleeding in people with NASH cirrhosis. About 845 adults with well-compensated cirrhosis will receive either the drug or a placebo. The goa…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Two-Drug combo aims to cure chronic hepatitis b
Disease control OngoingThis study tests whether giving two experimental drugs in sequence can achieve a functional cure for chronic hepatitis B. Participants are adults with chronic HBV who are already on standard antiviral therapy. They will receive either one of two doses of daplusiran/tomligisiran f…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New pill targets bile duct cancer that resists standard treatments
Disease control OngoingThis Phase 3 trial tests an oral drug called tinengotinib against standard treatments chosen by the doctor for people with advanced bile duct cancer (cholangiocarcinoma) that has a specific genetic alteration (FGFR) and has stopped responding to chemotherapy and an FGFR inhibitor…
Phase 3 • Sponsor: TransThera Sciences (Nanjing), Inc. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug may reverse liver damage in NASH patients
Disease control OngoingThis study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…
Phase 3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail shows promise for tough bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvat…
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo takes on tough liver cancers
Disease control OngoingThis study tests whether combining two drugs, domvanalimab and zimberelimab, can shrink or control advanced liver and bile duct cancers that have stopped responding to earlier treatments. About 58 adults with these cancers will receive the drug combination. The main goal is to se…
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy duo takes on bile duct cancer in new trial
Disease control CancelledThis Phase II trial tests whether adding two immunotherapy drugs (nivolumab and relatlimab) to standard chemotherapy can shrink tumors better than chemotherapy plus just one immunotherapy drug in people with advanced biliary tract cancer. The study will enroll 76 adults whose can…
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a single cell treatment free liver transplant patients from lifelong drugs?
Disease control OngoingThis study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejecti…
Phase 1/2 • Sponsor: Quell Therapeutics Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy targets untreatable liver cancer
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and bevacizumab) after a procedure that delivers tiny radioactive beads to the liver can help people with liver cancer that cannot be surgically removed. The study includes 58 participants and measures ho…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to fight untreatable liver cancer
Disease control OngoingThis phase 3 trial tests a combination of two immunotherapy drugs, durvalumab and tremelimumab, as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The study involves 214 Chinese patients and will measure safety, side effects, and how w…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo therapy aims to shrink untreatable liver tumors
Disease control OngoingThis phase II trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a radiation procedure called Y-90 SIRT can shrink liver tumors in people with intermediate-stage liver cancer that cannot be removed by surgery. About 55 participants will recei…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Pregnant women with hepatitis b: which drug is safer?
Disease control By invitation onlyThis study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…
Phase 4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Drug duo targets Hard-to-Treat IDH-Mutated tumors
Disease control OngoingThis phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior t…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase 1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy aims to stop small liver cancers from coming back
Disease control OngoingThis study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) before and after a standard tumor-burning procedure (radiofrequency ablation) can prevent small liver cancers from returning. About 202 adults with early-stage liver cancer will be randomly ass…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can targeted addiction care prevent alcohol relapse after liver transplant?
Disease control OngoingThis study tests whether a personalized addiction monitoring program helps liver transplant patients avoid serious alcohol relapse one year after surgery. Researchers will follow 64 adults who are being evaluated for a liver transplant at a French hospital. The program includes m…
Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to outsmart biliary cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs (sintilimab and ipilimumab) plus chemotherapy (albumin-bound paclitaxel and gemcitabine) as a first treatment for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery. The stu…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New immunotherapy combo aims to stop liver cancer return after surgery
Disease control OngoingThis phase II trial tests whether eparlitozoviril, a drug that blocks two immune checkpoints (PD-1 and CTLA-4), can prevent liver cancer from coming back after surgery in patients with microvascular invasion (MVI), a high-risk feature. About 60 participants will receive the drug …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Epigenetic drug may re-sensitize liver tumors to immunotherapy
Disease control OngoingThis phase 2 trial investigates whether adding an epigenetic drug (CXD101) to an immunotherapy (Geptanolimab) can help patients with advanced liver cancer whose disease has stopped responding to prior checkpoint inhibitors. The study enrolls about 26 adults with hepatocellular ca…
Phase 2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
Disease control OngoingThis phase 2 trial tests a combination of liver-directed chemotherapy (irinotecan liposome plus 5-FU/LV) with targeted therapy (lenvatinib) and immunotherapy (PD-1 inhibitors) as a first treatment for advanced intrahepatic cholangiocarcinoma, a rare and aggressive bile duct cance…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a hormone shield bile ducts in transplanted livers?
Disease control By invitation onlyThis trial investigates whether adding secretin—a hormone that helps produce bicarbonate—during machine perfusion of donor livers can restore the protective 'bicarbonate umbrella' in bile ducts. Researchers will treat up to 20 donor livers with secretin while they are kept on a m…
Phase 1/2 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Stomach balloon shows promise for fatty liver – but more proof needed
Disease control By invitation onlyThis study follows 200 people with nonalcoholic fatty liver disease (NAFLD) who receive an intragastric balloon—a device placed in the stomach to help with weight loss. Researchers will track changes in weight, liver enzymes, blood sugar, and liver stiffness for at least one year…
Sponsor: Methodist Health System • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Surgery vs. diet: which tames diabetes better?
Disease control OngoingThis study compares two types of weight-loss surgery (gastric bypass and gastric banding) with an intensive diet and exercise program for controlling type 2 diabetes in moderately obese adults aged 25 to 55. The goal is to see which approach works best for improving diabetes and …
Sponsor: University of Pittsburgh • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cold climate liver cancer study tests new drug combos
Disease control OngoingThis study looks at how well immunotherapy drug combinations work for people with liver cancer living in cold parts of China. Researchers will track 1,000 patients to see if these treatments help them live longer and slow cancer growth. The goal is to find the best treatment plan…
Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Which catheter delivers better chemo to liver tumors? small trial aims to find out
Disease control OngoingThis trial compares two FDA-approved catheters used during TACE, a procedure that delivers chemotherapy directly to liver tumors. Twelve participants with liver cancer or neuroendocrine tumors will receive two TACE procedures, each using a different catheter. The goal is to see w…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New radioactive beads aim to outperform standard liver cancer therapy
Disease control OngoingThis Phase 3 trial compares a new treatment called NRT6003 (tiny radioactive beads) against the standard chemoembolization (cTACE) for people with liver cancer that cannot be removed by surgery. About 108 participants will receive either the new beads or the standard procedure. T…
Phase 3 • Sponsor: Chengdu New Radiomedicine Technology Co. LTD. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Triple threat: drug cocktail and precision radiation take on tough bile duct cancer
Disease control OngoingThis phase II trial tests a combination of two drugs (anlotinib and cadonilimab) plus a special type of radiation (PULSAR) in 26 people with advanced bile duct cancer that has worsened after standard treatment. The goal is to see if this triple therapy can shrink tumors and contr…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Can a formula diet reverse fatty liver damage?
Disease control OngoingThis study tests whether a special formula diet can help people with non-alcoholic fatty liver disease (NASH) lose weight and improve liver health. About 20 overweight adults will follow the diet to see if it reduces liver fat and scarring. The goal is to find a safe, effective w…
Sponsor: West German Center of Diabetes and Health • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Finger-Prick test could speed up hepatitis c treatment
Disease control OngoingThis study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …
Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Immune cells take on rare bile duct cancer in early trial
Disease control OngoingThis early-phase trial tests whether a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), can shrink advanced bile duct cancers. Four participants receive chemotherapy to prepare their immune system, then an infusion of their own TIL cells plus high-dose ald…
Phase 2 • Sponsor: Udai Kammula • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New shot could shrink enlarged livers and ease pain
Disease control OngoingThis study tests a drug called CAM2029 (octreotide) given as a weekly or every-other-week shot to people with symptomatic polycystic liver disease. The goal is to see if it can shrink the liver and reduce symptoms like belly pain, bloating, and nausea. About 71 adults with an enl…
Phase 2/3 • Sponsor: Camurus AB • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Hope for NASH: new pill aims to reverse liver damage and prevent cirrhosis
Disease control OngoingThis Phase 3 trial tests whether the drug resmetirom (MGL-3196) can reverse liver scarring (fibrosis) and stop NASH from progressing to cirrhosis or liver failure. About 1,759 adults with NASH and liver fibrosis will receive either resmetirom or a placebo daily for up to 54 month…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for untreatable liver tumors
Disease control OngoingThis phase 2 trial tests a combination of two drugs (donafenib and sintilimab) plus a procedure called TACE in 48 adults with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors and control the disease. The study is…
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail of drugs shows promise for bile duct cancer
Disease control OngoingThis study tests a new drug combination for people with advanced biliary tract cancer (bile duct cancer) who haven't had treatment before. About 93 participants will receive either a standard chemotherapy plus two immunotherapy drugs, or the same plus an extra experimental drug. …
Phase 2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a simple wash during surgery extend lives of pancreatic cancer patients?
Disease control OngoingThis study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cocktail aims to make liver cancer operable
Disease control PausedThis study tests a combination of chemotherapy, immunotherapy, and a targeted drug given directly into the liver's blood supply to shrink tumors in people with liver cancer that may be removable with surgery. The goal is to see if this approach can make surgery more effective and…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New blood filter shows promise for liver failure patients
Disease control OngoingThis study tests a blood-filtering treatment called DPMAS for people with severe liver failure. The goal is to see if it can lower the risk of death or worsening disease within weeks. About 1300 adults with chronic liver disease and high bilirubin levels are taking part. Research…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill shows promise for fatty liver in major trial
Disease control OngoingThis study tests a daily pill called resmetirom in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it safely reduces liver fat and cholesterol over 52 weeks. About 810 adults who completed earlier related studies are taking part. This is a long-term t…
Phase 3 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Online diet program shows promise for fatty liver
Disease control OngoingThis study tested whether a 12-week online Mediterranean diet program could reduce liver fat in people with a type of fatty liver disease (MASLD). 78 adults followed either the diet program or received standard advice. The goal was to see if the diet could improve liver health an…
Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a simple antiviral stop hepatitis b from waking up in lymphoma patients?
Disease control OngoingThis study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to shrink GI cancers before surgery
Disease control OngoingThis phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…
Phase 2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New registry monitors liver transplant device in thousands of patients
Disease control By invitation onlyThis study is a registry that collects information from up to 5,000 people who received a liver transplant after the donated liver was treated with the VitaSmart HOPE system. The device keeps the liver cool and oxygenated before transplant. The goal is to see how well the device …
Sponsor: Bridge to Life Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise for untreatable liver cancer
Disease control OngoingThis early-phase study tests whether adding an experimental drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) is safe and effective for people with advanced liver cancer that cannot be removed by surgery. About 43 adults who have not had prior syst…
Phase 1 • Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New imaging tech aims to sharpen liver cancer radiation
Disease control OngoingThis study looks at whether a special imaging technique called KIM can help doctors deliver radiation more accurately to liver tumors. About 32 adults with liver cancer who cannot have surgery or a transplant will receive radiation with and without KIM tracking. The goal is to se…
Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could nopal, cacao, and cricket help fatty liver?
Disease control By invitation onlyThis study tests a supplement made from nopal, cacao, and cricket in 60 adults with fatty liver disease (MASLD). Participants take the supplement or a placebo daily for 3 months, along with dietary guidance. The goal is to see if the supplement reduces liver fat, improves health …
Sponsor: University of Guadalajara • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for kids with rare liver tumors: tailored therapy trial shows promise
Disease control OngoingThis study tests different treatment plans based on each child's risk level for two rare liver cancers: hepatoblastoma and hepatocellular carcinoma. About 450 children will receive chemotherapy and possibly surgery, with the goal of preventing the cancer from coming back. The app…
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for bile duct cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug IBI362 takes on semaglutide in fatty liver showdown
Disease control OngoingThis study tests whether a new weekly injection called IBI362 works better than the existing drug semaglutide for weight loss and reducing liver fat in overweight or obese Chinese adults with metabolic dysfunction-associated fatty liver disease (MAFLD). About 479 participants wil…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Triple therapy shows promise for untreatable liver cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (lenvatinib) as a first treatment for people with advanced liver cancer that cannot be surgically removed. The study enrolled 114 participants and is activ…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Hope for liver disease: new drug trial targets PBC symptoms
Disease control OngoingThis study tests a drug called saroglitazar magnesium in people with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug is safe and helps control the disease. About 102 adults who completed a previous PBC study will take the drug and be mon…
Phase 3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could hepatitis c positive lungs save lives? pilot study explores new transplant option
Disease control OngoingThis study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …
Early phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Liver transplant bleeding study pulled before starting
Disease control CancelledThis study was designed to see if a new concentrated fibrinogen product works better than the standard one for controlling bleeding in liver transplant patients. It planned to enroll adults having a cadaveric liver transplant who were at risk for low fibrinogen levels. However, t…
Phase 4 • Sponsor: Ezeldeen Abuelkasem • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Universal CAR-T therapy targets Hard-to-Treat liver and lung cancers
Disease control PausedThis early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…
Early phase 1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug cocktail aims to shrink Hard-to-Treat liver and bile duct tumors
Disease control OngoingThis phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation can shrink tumors in people with advanced liver or bile duct cancer. The study enrolled 37 adults whose cancer had spread or could not be removed by surgery. The goal i…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo tackles liver cancer after standard drug fails
Disease control OngoingThis phase 2 trial is testing whether adding doxorubicin to sorafenib can help people with advanced liver cancer whose disease has progressed while on sorafenib alone. The study enrolls 30 adults with confirmed liver cancer and Child-Pugh A cirrhosis or no cirrhosis. Researchers …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Liver-Directed chemo shows promise for eye cancer metastases
Disease control OngoingThis phase 2 trial tests a procedure called transarterial chemoembolization (TACE) for people with uveal melanoma that has spread to the liver. Doctors inject a chemotherapy drug (carmustine) mixed with an oily contrast agent (Lipiodol) directly into the liver's blood supply, the…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Water pill could boost liver cancer treatment
Disease control OngoingThis early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for transplant patients with hepatitis b: safer drug switch under study
Disease control OngoingThis study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…
Phase 4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a targeted drug beat standard care for shock in liver patients?
Disease control OngoingThis study tests whether a drug called Angiotensin II can raise blood pressure more effectively than standard medications in people with liver cirrhosis who have septic shock. Researchers will measure how well the heart and blood vessels work together over 24 hours. The trial inv…
Early phase 1 • Sponsor: The Cleveland Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Reishi mushroom tested as fatty liver treatment in new study
Disease control By invitation onlyThis study tests whether Ganoderma lucidum (a type of mushroom) can improve antioxidant levels and liver health in people with Metabolic Associated Fatty Liver Disease (MAFLD). Forty adults aged 35-49 with early-stage fatty liver will take the mushroom supplement. Researchers wil…
Sponsor: University of Agriculture, Peshawar • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Second chance: new combo aims to clear hepatitis c after relapse
Disease control OngoingThis study tests a 12-week course of three antiviral drugs (sofosbuvir, velpatasvir, and voxilaprevir) in 200 adults with chronic hepatitis C whose virus returned after previous treatment. The main goal is to see if the virus becomes undetectable 12 weeks after therapy ends. Rese…
Sponsor: Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Common heart drug may stop deadly bleeding in liver patients
Disease control OngoingThis study tests whether beta-blockers, a type of blood pressure medicine, can reduce the risk of bleeding from small varices in people with cirrhosis and portal hypertension. About 763 adults with small varices will receive either beta-blockers or a placebo for up to 3 years. Th…
Phase 4 • Sponsor: King's College Hospital NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
App-tastic hope: smartphone tool aims to shrink fatty livers
Disease control OngoingThis study tests whether a smartphone app can help Chinese adults with non-alcoholic fatty liver disease (NAFLD) lose weight over 12 months. Weight loss is currently the only proven way to reverse liver fat and prevent serious complications. The trial will enroll 260 participants…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Could a common diabetes drug help drain dangerous belly fluid?
Disease control OngoingThis study looks at whether SGLT2 inhibitors, a type of diabetes medication, can help control ascites (fluid buildup in the belly) in people with liver cirrhosis and type 2 diabetes. Researchers will compare 40 patients who add the drug to their usual treatment against those who …
Sponsor: University of Palermo • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental combo targets tough liver cancer
Disease control OngoingThis early trial tests whether combining the drug lenvatinib with a new experimental drug, VIC-1911, is safe and can shrink tumors in people with advanced liver cancer. Only 12 participants will be enrolled, and the study is open-label, meaning everyone gets the combination. The …
Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for liver cancer patients resistant to standard therapy
Disease control OngoingThis study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for hepatitis b: Real-World trial of pradefovir underway
Disease control OngoingThis study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 wee…
Sponsor: Juan Li • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Immunotherapy combo may boost liver cancer ablation outcomes
Disease control OngoingThis phase 2 trial tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before and after a standard ablation procedure can help prevent liver cancer from returning. Thirty adults with early-stage liver cancer will receive one infusion of the drug combination…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stomach stitching without surgery: can it reverse fatty liver?
Disease control OngoingThis study looks at whether a non-surgical stomach-reducing procedure called endoscopic sleeve gastroplasty (ESG) can help obese people with nonalcoholic fatty liver disease lose weight and improve liver health. Researchers will measure changes in liver fat and stiffness, as well…
Sponsor: West Virginia University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy hepatitis b drug showdown: which is safer for mom and baby?
Disease control By invitation onlyThis study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy a…
Phase 4 • Sponsor: The Third Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made DNA vaccine takes on advanced liver cancer
Disease control OngoingThis study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…
Phase 1/2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Gene editing for hepatitis b: researchers track Long-Term safety
Disease control By invitation onlyThis study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…
Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Diet or drugs? new study tests if fasting beats pills for fatty liver disease
Disease control By invitation onlyThis study tests whether a Mediterranean diet combined with intermittent fasting can reduce liver scarring (fibrosis) better than the weight-loss medication naltrexone/bupropion. About 70 adults with overweight or obesity and heart or metabolic risks (like type 2 diabetes or high…
Phase 4 • Sponsor: Carmen Dietvorst • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Peer support after prison may boost hepatitis c care
Disease control OngoingThis study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…
Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Can a keto diet help obese patients with advanced liver disease?
Disease control OngoingThis study tests whether a monitored ketogenic diet is safe and effective for weight loss in 40 obese adults with compensated NASH cirrhosis. Participants are randomly assigned to either a ketogenic diet or standard dietary advice for 16 weeks. The main goals are to check for liv…
Sponsor: Indiana University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase 1/2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Cash for sobriety: new trial aims to keep transplant patients off alcohol
Disease control OngoingThis study tests a behavioral program called contingency management for people who have had a liver transplant due to alcohol-related liver disease and have started drinking again. Participants get rewards like gift cards for staying alcohol-free, measured by urine and blood test…
Sponsor: Arpan A. Patel, MD • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Pregnant women with hepatitis c get new hope from 12-Week drug trial
Disease control OngoingThis study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and …
Phase 4 • Sponsor: Catherine Anne Chappell • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a weekly shot help obese teens avoid diabetes and fatty liver?
Disease control OngoingThis study tests whether semaglutide (Wegovy), a once-weekly injection, can preserve the pancreas's ability to produce insulin and reduce liver fat in 60 obese youth with prediabetes or early type 2 diabetes and fatty liver disease. Participants receive either semaglutide or a pl…
Phase 2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gut health fix for HIV fatty liver? early trial tests probiotics
Disease control OngoingThis early-phase study tests whether taking prebiotic fiber and probiotics can improve fatty liver disease in people with HIV. Researchers believe changes in gut bacteria may contribute to liver problems. The trial involves 63 participants and measures liver fat and gut health ma…
Early phase 1 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New electrode aims to safely burn away small liver tumors
Disease control OngoingThis study tests a special electrode for radiofrequency ablation in people with small liver cancers (3 cm or less). The electrode monitors temperature and can adjust its tip to match tumor shape, aiming to destroy the tumor while protecting nearby organs. Researchers will track w…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could a lung drug save kidneys in liver patients?
Disease control OngoingThis study tests whether ambrisentan, a drug approved for lung blood pressure, can help patients with hepatorenal syndrome—a serious kidney problem that can occur in advanced liver cirrhosis. About 54 hospitalized adults will receive either ambrisentan or the standard drug terlip…
Phase 2 • Sponsor: Noorik Biopharmaceuticals AG • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for liver cancer in hepatitis b patients
Disease control OngoingThis study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…
Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Pig liver keeps patient alive in World-First Bridge-to-Transplant trial
Disease control OngoingThis early-phase trial tests whether a gene-edited pig liver, used outside the body like a dialysis machine, can temporarily support liver function in one person with severe liver failure. The goal is to keep the patient stable until a human liver transplant becomes available. Pa…
Early phase 1 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Peer-led program aims to cut overdose deaths with drug checking and safer use habits
Disease control OngoingThis study tests a program where trained peers use motivational interviewing to encourage people who use drugs to check their drugs for dangerous substances and adopt safer use behaviors. The goal is to reduce fatal and non-fatal overdoses, as well as HIV and hepatitis C infectio…
Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Immune drugs given before surgery show promise against multiple cancers
Disease control OngoingThis phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Can a popular diabetes drug help liver transplant patients control blood sugar?
Disease control By invitation onlyThis study compares two diabetes medications, semaglutide and sitagliptin, in 58 adults who have had a liver transplant and have poorly controlled diabetes. The goal is to see which drug better lowers blood sugar and body weight. Participants will take the study drug daily for th…
Phase 4 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo aims to unleash immune system on liver cancer
Disease control OngoingThis phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or canno…
Phase 2 • Sponsor: University of Hawaii • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase 1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation approach targets liver tumors without surgery
Disease control OngoingThis study tests a precise type of radiation called SBRT for people with liver cancer or tumors that have spread to the liver. It includes 280 participants with various liver tumor types. The goal is to see how well SBRT controls tumor growth and what side effects occur.
Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cocktail targets HER2-Positive bile duct cancer in small trial
Disease control OngoingThis phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participant…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New dosing strategy aims to make liver cancer drug easier to tolerate
Disease control OngoingThis phase 2 trial tests whether slowly increasing the dose of the cancer drug regorafenib helps patients with advanced liver cancer tolerate it better. About 28 adults who have already tried one prior treatment will start at a low dose and increase weekly. The main goal is to se…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Chemo-Oil combo shows promise for liver cancer patients who Can't have surgery
Disease control OngoingThis study tests a new, stable mixture of chemotherapy drug and iodized oil for treating early-stage liver cancer in people who cannot or choose not to have surgery. The treatment combines TACE (a procedure that blocks the tumor's blood supply and delivers chemo directly) with he…
Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a Step-by-Step program help latinos beat fatty liver?
Disease control OngoingThis study looks at whether a 26-week behavioral weight loss program called 'Paso a Paso' is practical for Mexican and Central American adults with fatty liver disease and overweight. Researchers will track attendance, weight loss, liver stiffness, and diet changes in 50 particip…
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cell injection aims to repair damaged livers in early trial
Disease control By invitation onlyThis early-phase trial tests a single injection of HCL001 cells in 39 people with decompensated cirrhosis, a severe form of liver disease. The study aims to check safety and see if the treatment can improve liver function. Participants receive one of three dose levels, and resear…
Phase 1/2 • Sponsor: Shanghai Huicun Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple drug cut dangerous blood pressure swings in liver transplants?
Disease control OngoingThis study tests whether a drug called Angiotensin II can help control blood pressure during liver transplant surgery, reducing the need for other strong blood pressure medicines. It involves 50 adults with severe liver disease who are receiving a liver from a deceased donor. The…
Phase 2/3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
AI coach for transplant patients: will it cut hospital stays?
Disease control By invitation onlyThis study tests a smartphone app that uses artificial intelligence to help liver transplant recipients manage their health after surgery. Researchers will track whether the app improves patients' confidence, daily self-care, and quality of life, and reduces emergency visits or i…
Sponsor: Chang Gung University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for liver cancer patients: which procedure best prevents dangerous rebleeding?
Disease control OngoingThis study looks at 70 people with liver cancer who had bleeding from enlarged veins in the esophagus. It compares two procedures—an ultrasound-guided injection of a glue-like substance versus a banding technique—to see which better prevents future bleeding. The goal is to find t…
Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a cancer drug help cure hepatitis b? new trial launches
Disease control OngoingThis pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…
Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill for fatty liver disease enters first human tests
Disease control OngoingThis early-stage study tests a new drug called CS060304 in healthy volunteers and people with high LDL-C (bad cholesterol), a risk factor for MASH (a serious liver disease). The main goal is to check if the drug is safe and how the body processes it. 80 participants will receive …
Phase 1 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug YL201 enters human testing for advanced tumors
Disease control OngoingThis study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.
Phase 1/2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for liver cancer patients who stop responding to immunotherapy?
Disease control OngoingThis phase II trial tests the drug cabozantinib in 20 people with advanced liver cancer (HCC) whose disease got worse after immunotherapy. The goal is to see if cabozantinib can slow tumor growth and improve survival. It is a small, early study, so results are not yet conclusive.
Phase 2 • Sponsor: Stephen Chan Lam • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Immunotherapy duo takes on rare cancers
Disease control OngoingThis Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…
Phase 2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for hepatitis b patients: switching to TAF after relapse
Disease control OngoingThis study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patient…
Phase 4 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study aims to help cancer survivors manage other health problems
Disease control OngoingThis study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …
Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug aramchol aims to reverse fatty liver damage in phase 3 trial
Disease control PausedThis study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see …
Phase 3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Radioactive beads offer new hope for inoperable liver cancer
Disease control OngoingThis study tests a treatment called selective internal radiation therapy (SIRT) for people with liver cancer that cannot be removed by surgery. Tiny radioactive beads are injected into the liver to deliver radiation directly to tumors. The goal is to shrink the cancer and control…
Sponsor: Sirtex Medical • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cancer pill may boost ablation success in aggressive liver tumors
Disease control OngoingThis study tests whether the targeted drug lenvatinib, given before and after a standard tumor-burning procedure (ablation), can help prevent liver cancer from returning in patients with aggressive tumors. About 32 adults with high-risk features (like high AFP levels or infiltrat…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a statin tame fatty liver disease? new trial seeks answers
Disease control OngoingThis study tests whether atorvastatin (Lipitor), a widely used cholesterol medication, can safely improve liver damage in people with NASH, a serious fatty liver disease. About 70 adults with confirmed NASH and liver scarring will receive either the drug or a placebo. The goal is…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug combo aims to free hepatitis b patients from daily pills
Disease control OngoingThis Phase 2 trial tests whether a new injection called BW-20507, combined with pegylated interferon alfa, can help people with chronic hepatitis B stop their daily antiviral medication (NUCs). About 209 adults with hepatitis B will receive the combination for 48 weeks. The main …
Phase 2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo attack: surgery and drugs take on tough liver cancer
Disease control OngoingThis phase 3 trial is testing whether liver surgery followed by two drugs (atezolizumab and bevacizumab) can help people with liver cancer that has spread into veins. The study includes 501 participants who have not had prior treatment. The goal is to see if this approach delays …
Phase 3 • Sponsor: Jia Fan • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Sound waves zapping liver tumors? new device tested in 24 patients
Disease control OngoingThis trial tests a device called HistoSonics that uses focused ultrasound (sound waves) to mechanically destroy liver tumors without heat or needles. It includes 24 adults with liver cancer or tumors that spread to the liver. The main goals are to see if the device can fully cove…
Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Common statin may ward off liver failure in veterans
Disease control OngoingThis study tests whether simvastatin, a drug typically used for cholesterol, can reduce the risk of liver complications in veterans with compensated cirrhosis (scarred but symptom-free liver). About 142 participants will take either simvastatin or a placebo nightly for several ye…
Phase 3 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immunotherapy cocktail aims to fight untreatable liver cancer
Disease control OngoingThis phase 3 trial is testing whether adding tiragolumab to the standard combination of atezolizumab and bevacizumab helps people with advanced liver cancer that cannot be surgically removed. About 687 participants will receive either the three-drug combo or the two-drug combo pl…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug shows promise against rare liver infection
Disease control OngoingThis Phase 2 trial tests a new drug called hepalatide (L47) in 90 adults with chronic hepatitis D, a serious liver infection. Participants receive either a low or high dose of hepalatide daily for 48 weeks, or delayed treatment. The main goal is to see if the drug can lower the v…
Phase 2 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Herbal mix plus tenofovir shows promise for hepatitis b control
Disease control ApprovedThis study looks at whether a combination of four herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata, and ascorbic acid) plus the drug tenofovir can help control hepatitis B over the long term. The treatment aims to strengthen the immune system and reduce virus l…
Sponsor: Nguyen Thi Trieu, MD • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for early liver cancer: radioembolization under the microscope
Disease control OngoingThis study looks at how well a treatment called 90Y radioembolization works for people with early-stage liver cancer. Researchers will track 200 patients in Korea to see how the tumors respond, how long patients live, and any side effects. The goal is to gather real-world data to…
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail aims to fight advanced liver cancer
Disease control OngoingThis phase 3 study tests whether a combination of cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy) works better than the standard drug sorafenib for people with advanced liver cancer who haven't had prior systemic treatment. About 837 adults are taking part. …
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase 1/2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New hope for kids with hepatitis c: drug combo trial launches in cambodia
Disease control OngoingThis study is testing a combination of two antiviral drugs, sofosbuvir and daclatasvir, in children aged 6 and older with active hepatitis C in Cambodia. The goal is to see if the treatment can clear the virus from the blood 12 weeks after finishing the 12-week course. The trial …
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Exercise over pills: new study tests if moving more can shrink fatty liver
Disease control OngoingThis pilot study is testing whether a 24-week program of adapted physical activity, combined with diet advice, can reduce liver fat in 115 adults with non-alcoholic fatty liver disease (NAFLD). Participants will follow personalized exercise and diet plans, and researchers will me…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New combo therapy aims to shrink liver tumors before surgery
Disease control CancelledThis early-phase study tests a new treatment for advanced liver cancer. Participants will receive focused radiation to the tumor along with two immunotherapy drugs (tremelimumab and durvalumab) to help the immune system fight the cancer. The goal is to see if this combination is …
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Sound waves zapping liver tumors: no knife needed?
Disease control OngoingThis trial tests a device called HistoSonics that uses focused ultrasound waves to mechanically destroy liver tumors without heat, needles, or incisions. About 47 adults with liver cancer or tumors that spread to the liver will receive this treatment. The main goals are to see if…
Sponsor: HistoSonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for hepatitis b patients with normal ALT: TMF drug trial underway
Disease control OngoingThis study tests a drug called Tenofovir Amibufenamide (TMF) in 200 adults with chronic hepatitis B who have normal liver enzyme levels (ALT). The goal is to see if TMF can lower the virus to undetectable levels and possibly clear the hepatitis B surface antigen. Participants are…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New immunotherapy aims to fight advanced liver cancer
Disease control PausedThis study tests an immunotherapy called AlloStim against standard treatments (sorafenib, lenvatinib, or chemotherapy) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. Participants are randomly assigned to receive either AlloS…
Phase 2/3 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise for untreatable liver cancer
Disease control OngoingThis study looks at how well a combination of two drugs (atezolizumab and bevacizumab) plus local treatments like chemo or radiation works for people with advanced liver cancer that can't be removed by surgery. About 1,136 patients from hospitals in China and Asia will be include…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Muscle-Building amino acids tested in liver disease patients
Disease control By invitation onlyThis study tests whether taking branched-chain amino acid (BCAA) supplements for 24 weeks can help people with liver cirrhosis who have low muscle mass (sarcopenia) regain muscle and improve strength. About 86 adults aged 18–85 will be randomly assigned to receive either BCAA or …
Phase 3 • Sponsor: Mahidol University • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New coated mesh aims to stop implants from poking through skin
Disease control OngoingThis study tests whether a polyester mesh coated with fluoropolymer can reduce complications after breast reconstruction in women with breast cancer. One hundred women will receive either standard reconstruction or reconstruction with the coated mesh. The main goal is to see if t…
Sponsor: Saint Petersburg State University, Russia • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Engineered t cells take on childhood liver cancer in first human test
Disease control OngoingThis early-phase trial tests a new experimental treatment called GAP T cells in children and young adults with liver cancer that has come back or not responded to standard therapy. The cells are made from the patient's own immune T cells, which are genetically modified to recogni…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 26, 2026 18:58 UTC
-
Exercise program aims to boost liver transplant recovery
Disease control By invitation onlyThis study tests whether a supervised exercise program before and after liver transplant can help patients recover faster and have fewer complications. Sixty adults awaiting a liver transplant will take part. The program includes aerobic, muscle, and balance exercises for 8 weeks…
Sponsor: Maria dels Angels Cebria i Iranzo, PT, PhD • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
New hope for liver patients: drug may delay brain fog and hospital stays
Disease control OngoingThis Phase 3 study tests whether a special form of the antibiotic rifaximin can delay the first episode of overt hepatic encephalopathy (brain dysfunction) in people with liver cirrhosis who have controlled fluid buildup in the belly. About 466 participants will receive either ri…
Phase 3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
French cities launch community push to wipe out hepatitis c in drug users
Disease control OngoingThis study aims to eliminate hepatitis C among people who use drugs in Paris, Marseille, Lyon, and Fort-de-France. Researchers will screen participants, provide immediate treatment, and use a peer-referral system to reach more people. The goal is to see if this community-based ap…
Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 26, 2026 14:26 UTC
-
Cancer combo trial pulled before it even started
Disease control CancelledThis study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…
Phase 2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 26, 2026 13:13 UTC
-
Blood thinner flush could boost tumor biopsy success
Diagnosis CancelledResearchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
AI reads CT scans to spot liver cancer before It's too late
Diagnosis OngoingThis study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…
Sponsor: Zhejiang University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
AI-Powered Low-Dose CT could spare cancer patients unnecessary radiation
Diagnosis OngoingThis study tests whether a low-radiation CT scan, enhanced with artificial intelligence software, can detect liver tumors as accurately as a standard CT scan. About 146 adults with colorectal cancer and known liver metastases will receive both scans. The goal is to see if the low…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New blood panel aims to catch liver cancer before it spreads
Diagnosis OngoingResearchers are testing a blood test panel called Glycotest HCC to see if it detects early-stage liver cancer better than the standard alpha-fetoprotein (AFP) test. The study includes 766 people with cirrhosis, some of whom have early liver cancer and some who do not. Participant…
Sponsor: Glycotest, Inc. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
AI and blood biomarkers could catch hidden liver damage
Diagnosis OngoingThis study tests whether combining artificial intelligence with blood biomarkers can improve the detection of compensated advanced chronic liver disease (cACLD) in people with fatty liver disease. Researchers will enroll 408 adults with dysmetabolic liver disease and compare stan…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New PET scan could help match liver transplants to right patients
Diagnosis OngoingThis study looks at whether a special PET scan using two tracers (FDG and Choline) can improve how doctors decide which liver cancer patients should get a liver transplant. The trial involves 108 patients from two hospitals in France. The goal is to see if this scan catches cance…
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jul 19, 2026 00:00 UTC
-
Blood test aims to outshine ultrasound for liver cancer detection
Diagnosis OngoingThis trial is testing a blood test that looks for DNA markers of liver cancer in people with liver cirrhosis, who are at high risk for developing the disease. The test is compared to standard ultrasound to see which method is better at detecting liver cancer. If the blood test pr…
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
AI could spot liver cancer types and predict survival without needle biopsy
Diagnosis OngoingThis study is developing an artificial intelligence system that combines CT/MRI scans, lab results, and radiology reports to help diagnose liver cancer and predict how patients will fare after surgery. The AI aims to distinguish benign from malignant liver lesions and differentia…
Sponsor: Guangxi Medical University • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Simple blood test could spot hidden liver damage before It's too late
Diagnosis OngoingThis study is testing a two-step screening process to find liver scarring (fibrosis) in people aged 40 and older who have risk factors like heavy drinking, diabetes, or metabolic syndrome but no known liver disease. First, participants get a blood test to calculate a FIB-4 score;…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
AI spots hidden liver disease in routine scans
Diagnosis By invitation onlyThis study tests whether an AI system can help doctors identify patients with fatty liver disease who need specialist care. About 8,000 adults getting routine CT scans will have their images analyzed by AI to flag those at risk. The goal is to see if AI can improve detection and …
Sponsor: Shengjing Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
AI spots silent liver danger in ER scans
Diagnosis By invitation onlyThis study tests a computer system that automatically finds fatty liver disease on emergency room scans and alerts doctors to tell patients and arrange follow-up care. About 4,700 adults with fatty liver seen on an ER scan will take part. The goal is to improve how often this hid…
Sponsor: Northwestern University • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New imaging study aims to spot liver trouble in obese kids without needles
Diagnosis By invitation onlyThis study follows 300 children aged 9 to 14 with obesity to see if ultrasound and MRI can detect early signs of liver disease. Researchers will compare imaging markers like liver fat and stiffness with standard tests. The goal is to improve diagnosis and monitoring without invas…
Sponsor: Sahlgrenska University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
Simple blood test could spot hidden liver disease in women
Diagnosis OngoingThis study is testing a reflex blood test to find primary biliary cholangitis (PBC) earlier in women aged 40 and older. When routine blood work shows certain liver enzyme elevations, the lab automatically checks for antibodies linked to PBC. The goal is to see if this automatic f…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New blood test aims to catch liver cancer recurrence early
Diagnosis OngoingThis study is testing a new blood test that looks for DNA changes to detect if liver cancer has come back or spread after surgery. Researchers at Mayo Clinic are enrolling 36 patients with early-stage liver cancer who are scheduled for surgery. The goal is to see if this test can…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Blood test boosts liver cancer detection in High-Risk patients
Diagnosis By invitation onlyThis study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…
Sponsor: Siriraj Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New MRI scan could replace painful liver biopsies for MASH patients
Diagnosis By invitation onlyThis study aims to see if a special MRI scan can accurately detect liver scarring (fibrosis) in people with a liver condition called MASH. Researchers will compare the MRI results with standard tests like ultrasound and blood work in 50 adults. If successful, this could offer a n…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New MRI dye could sharpen liver lesion detection
Diagnosis By invitation onlyThis study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion v…
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Biopsy needle showdown: which tool gets the best tissue sample?
Diagnosis CancelledThis study aimed to compare two different needles used to take tissue samples from solid masses in the pancreas and digestive tract. The goal was to see which needle provides a more accurate diagnosis. The study was planned for adults needing this procedure, but it was withdrawn …
Sponsor: Thomas Jefferson University • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Blood test breakthrough could end painful liver biopsies for NASH patients
Diagnosis OngoingThis study looks at whether two blood markers, PLIN2 and RAB14, can accurately diagnose NASH (a serious liver disease) and advanced scarring, without needing a liver biopsy. Researchers will test these markers in 828 adults with NASH, type 2 diabetes, or obesity. If successful, t…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
One Breath-Hold MRI could replace liver biopsies for NASH
Diagnosis OngoingThis study tests a new MRI technique that measures liver fat, fibrosis, and inflammation in a single 14-second breath-hold, without needles or contrast dye. Researchers will scan 120 people with fatty liver disease (60 with simple steatosis and 60 with NASH) and compare results t…
Sponsor: Chinese University of Hong Kong • Aim: Diagnosis
Last updated Jun 27, 2026 11:02 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
New hope: antiviral cocktail may block hepatitis b in newborns
Prevention OngoingThis phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce moth…
Phase 3 • Sponsor: University of Alabama at Birmingham • Aim: Prevention
Last updated Aug 26, 2026 00:00 UTC
-
Training the immune system to hunt down leftover liver cancer cells
Prevention OngoingThis phase 2 trial tests whether a vaccine made from a patient's own dendritic cells — immune cells trained to recognize liver cancer — can prevent the cancer from returning after surgical removal of the tumor. About 74 adults with a high risk of recurrence will receive the vacci…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
Peer-led prevention: can gancheros help stop HIV, hepatitis c, and overdose in NYC?
Prevention OngoingThis pilot trial tests whether training Gancheros—people who provide injection services in exchange for money or drugs—can lower HIV, hepatitis C, and overdose risks among migrant Puerto Rican people who inject drugs in New York City. Gancheros will attend six sessions on prevent…
Sponsor: North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC
-
One-Stop care may boost HIV and hep c treatment in drug users
Prevention OngoingThis study tests whether providing HIV prevention (PrEP) and hepatitis C treatment together at one location works better than sending patients to separate clinics. About 446 people who inject drugs will be randomly assigned to either on-site integrated care or off-site referrals …
Sponsor: Columbia University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Can a website help liver cancer patients care for themselves during chemoembolization?
Symptom relief OngoingResearchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for…
Sponsor: University Medical Center Ho Chi Minh City (UMC) • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
One-Day liver cancer treatment shows promise in early trial
Symptom relief OngoingThis early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can cold exposure melt away liver fat?
Symptom relief OngoingResearchers test whether repeated cold exposure using a water-perfused cooling suit can reduce liver fat and improve liver health in adults with metabolic dysfunction-associated steatohepatitis (MASH). Eleven participants wear the suit for about two hours daily over three months.…
Sponsor: Renmin Hospital of Wuhan University • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can an epidural pump beat IV painkillers after liver surgery?
Symptom relief OngoingThis trial compares two ways to control pain after open liver surgery: an epidural pump that delivers pain medicine near the spine, versus a standard IV pump. About 230 adults having elective open liver resection will be randomly assigned to one method. The goal is to see which a…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New stent study aims to ease jaundice in cancer patients
Symptom relief PausedThis study looks at whether a special stent (Hot AXIOS) can improve quality of life for people with bile duct blockages caused by cancer, when standard drainage fails. About 162 adults will receive the stent during an endoscopic procedure. The main goal is to see if jaundice symp…
Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
AR goggles help doctors hit the mark in liver biopsies
Symptom relief By invitation onlyThis study tests a new augmented reality system called LUMENA that helps doctors guide needles during MRI scans of the liver. Twenty adults having a liver biopsy or tumor ablation will try the device. The goal is to see if it is safe and works well enough to use in most procedure…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Could a simple electrical patch ease pain and depression in liver disease?
Symptom relief OngoingThis study is testing whether a device that delivers mild electrical stimulation through the skin (called TEA) can help with chronic pain and depression in people with cirrhosis. Thirty participants will use the device at home twice daily for 8 weeks, or a sham version. The main …
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New drug aims to lift fatigue and brain fog in liver disease patients
Symptom relief OngoingThis study tests a drug called golexanolone in 84 people with primary biliary cholangitis (PBC) who suffer from significant fatigue and cognitive problems. Participants receive either the drug or a placebo for up to 28 days. The goal is to see if the drug is safe and can improve …
Phase 1/2 • Sponsor: Umecrine Cognition AB • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
New pill aims to stop the relentless itch of a rare liver disease
Symptom relief OngoingThis study tests an experimental drug called volixibat for people with primary biliary cholangitis (PBC) who suffer from severe itching. The trial will involve 260 adults and compare volixibat against a placebo to see if it safely reduces itch severity and improves quality of lif…
Phase 2 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Can a smartwatch and nutrition coaching ease cirrhosis symptoms?
Symptom relief OngoingThis study tests a home monitoring program called LiverWatch for people with advanced liver disease (cirrhosis). Participants get a Fitbit, personalized nutrition advice, and weekly check-ins to boost activity and manage symptoms. The goal is to see if this approach improves qual…
Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Could a simple hat make jaundice treatment kinder for newborns?
Symptom relief By invitation onlyThis study tests whether a special hat with built-in goggles can make phototherapy more comfortable for full-term newborns with jaundice, compared to standard eye patches. Researchers will measure the babies' comfort levels, bilirubin changes, treatment duration, and parental sat…
Sponsor: Karamanoğlu Mehmetbey University • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Could a personal coach at home boost energy for cancer patients?
Symptom relief OngoingThis study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…
Sponsor: UNICANCER • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
New drug shows promise for relieving severe itch in liver disease
Symptom relief OngoingThis study tests the long-term safety of linerixibat, a drug for severe itching caused by primary biliary cholangitis (PBC). All 242 participants receive the drug openly. The goal is to see if it remains safe over time and improves quality of life.
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Home monitoring may keep cancer patients out of the ER
Symptom relief OngoingThis study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study compares two drainage techniques to ease jaundice in advanced cancer patients
Symptom relief PausedThis study compares two minimally invasive procedures to drain blocked bile ducts in patients with incurable cancer. One method drains the bile duct into the intestine, the other drains the gallbladder into the stomach. The goal is to see which approach causes fewer complications…
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New study tests safer bile duct drainage for cancer patients
Symptom relief PausedThis study compares two procedures to relieve bile duct blockage caused by cancer. About 120 patients with pancreatic or bile duct cancer will be randomly assigned to get either a newer ultrasound-guided drainage or the standard ERCP procedure. The goal is to see which method has…
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can one weekly workout beat fatty liver? new study tests the ideal exercise frequency
Symptom relief OngoingThis study looks at whether exercising once a week or three times a week is better at reducing liver fat in adults who are centrally obese and have non-alcoholic fatty liver disease (NAFLD). Three hundred Chinese adults aged 18-69 will be assigned to either a once-weekly or thric…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Tapping away the fear: EFT tested in rare bile duct cancer
Symptom relief OngoingThis early-phase study looks at whether Emotional Freedom Techniques (EFT) — a practice that combines tapping on acupressure points with counseling — can reduce anxiety, depression, pain, and insomnia in people with cholangiocarcinoma, a rare and aggressive bile duct cancer. Four…
Early phase 1 • Sponsor: Soul Medicine Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Pre-Surgery boot camp for liver cancer patients shows promise
Symptom relief By invitation onlyThis study tests a nurse-led program that starts at least a week before liver cancer surgery. It includes exercise, nutrition advice, mental support, and help quitting smoking or drinking. The goal is to see if this program helps patients stay stronger, feel less anxious, and hav…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Can a phone app help people with HIV beat fatty liver disease?
Symptom relief By invitation onlyThis study tests whether a mobile app-based nutritional program can help people living with HIV and fatty liver disease lose at least 5% of their body weight in 6 months. Participants are randomly assigned to use the app or receive standard lifestyle advice. The goal is to find a…
Sponsor: Hospital Universitari de Bellvitge • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New catheter aims to sharpen liver cancer radiation targeting
Knowledge-focused OngoingThis study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
500-Person study aims to crack the code of personalized weight loss
Knowledge-focused By invitation onlyThis study follows 500 obese adults to see how different factors like diet, exercise, stress, and sleep affect weight loss. Researchers collect blood tests, measurements, and questionnaires at the start and during follow-up. The goal is to find patterns that could lead to more pe…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Spanish databases used to map a rare liver disease
Knowledge-focused OngoingPrimary biliary cholangitis is a rare liver disease that slowly damages the bile ducts and can lead to cirrhosis or a liver transplant. Researchers are studying anonymised health records from about 3,000 adults in four Spanish databases to estimate how many people have the diseas…
Sponsor: Fundacio Privada Mon Clinic Barcelona • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can coaching turn rural clinics into One-Stop shops for addiction and infectious disease care?
Knowledge-focused OngoingResearchers are testing a coaching program to help primary care clinics in rural West Virginia screen and treat opioid use disorder, HIV, and hepatitis C. The program includes group priority-setting, rapid-cycle improvement coaching, and provider training. Twenty clinics will tak…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Web tool aims to empower rare cancer patients in genomic choices
Knowledge-focused OngoingThis study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Cured of hepatitis c? this study follows patients for 10 years to see what happens next
Knowledge-focused OngoingThis study follows 121 adults who have been cured of chronic hepatitis C to understand why some still develop liver complications like scarring or cancer. Participants are monitored for up to 10 years with regular tests, scans, and occasional liver biopsies. The goal is to learn …
Phase 4 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
New study analyzes Odevixibat's impact on rare liver disease outcomes
Knowledge-focused OngoingThis study looks at a rare liver disease called PFIC, which causes severe itching and liver damage. Researchers compare patients who took the drug odevixibat to those who did not, using data from past studies and a patient registry. The goal is to see if odevixibat helps avoid li…
Sponsor: Ipsen • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can gut microbes hold the key to liver health?
Knowledge-focused By invitation onlyResearchers at the University of Aberdeen are studying how the community of microbes in the gut, known as the gut microbiota, differs in people with liver disease compared to healthy controls. The liver receives blood from the gut, and changes in gut microbes may affect liver fun…
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Unapproved device tested in early trial
Knowledge-focused OngoingThis trial is testing a medical device that has not been approved or cleared by the U.S. FDA. The study is small and early-stage, focused on understanding how the device works and whether it is safe. No results are available yet, and the device is not ready for widespread use.
Sponsor: C. R. Bard • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New program aims to bridge the trust gap between oncologists and latino patients
Knowledge-focused By invitation onlyThis study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Epidiolex liver check: is Long-Term use safe?
Knowledge-focused OngoingThis study follows 154 people taking Epidiolex (cannabidiol) for seizures caused by Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Researchers will monitor for signs of chronic liver injury and fibrosis over time using blood tests and liver scans. The go…
Phase 4 • Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
1000 liver cancer patients enrolled in nationwide registry study
Knowledge-focused OngoingThe JADE study is a large registry that will follow 1,000 people with liver or bile duct cancer in Germany. Its goal is to collect information on how these cancers are actually treated in routine care, including treatments, outcomes, and patient quality of life. No experimental d…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Fatty liver to cancer: can genetics and lab-grown organoids reveal the trigger?
Knowledge-focused OngoingThis study explores why some people with fatty liver disease progress to severe liver damage and cancer. Researchers will analyze genetic data from over 35,000 patients and use lab-grown liver organoids to study fat droplets in liver cells. The goal is to identify genetic markers…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Blood tests could spot hidden liver risk in diabetics
Knowledge-focused OngoingThis completed study observed 40 people with type 2 diabetes to find blood markers that could identify those at risk for a serious liver condition called NASH. Researchers measured liver stiffness and calculated scores like FIB-4 and ELF to see which patients might have liver sca…
Sponsor: Faculty Hospital Kralovske Vinohrady • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Why are some patients left off the liver transplant list? mayo clinic launches investigation
Knowledge-focused OngoingThis study from Mayo Clinic aims to understand the individual and social reasons why some patients with end-stage liver disease are not listed for or do not receive a liver transplant. Researchers will track 100 patients to see who gets on the waiting list, who receives a transpl…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
HIV and hidden health risks: a major study probes the link
Knowledge-focused OngoingThis study compares over 1,500 people living with HIV to a similar group from the general population to see if conditions like heart disease, COPD, and liver disease are more common or develop faster in those with HIV. Using detailed scans and tests, researchers will measure the …
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can smarter surgical tools cut liver surgery risks?
Knowledge-focused By invitation onlyThis study looks back at the records of about 800 adults who had minimally invasive liver surgery (laparoscopic, robotic, or hybrid) at specialized Italian centers. The goal is to see how the choice of surgical tools and techniques for cutting liver tissue relates to the risk of …
Sponsor: University of Molise • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can hormone therapy change liver health? a new study investigates
Knowledge-focused By invitation onlyThis study looks at liver health in transgender people who are on gender-affirming hormone therapy (GAHT). It compares those who have been on hormones for more than six months with those on them for less time. Researchers will measure liver function through blood tests and a spec…
Sponsor: Corey DeStefano • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Liver scan changes may foretell deadly complications
Knowledge-focused OngoingThis study looks at medical records from 10,000 adults with MASLD or MASH, a common liver condition. Researchers will check if changes in liver stiffness, measured by a non-invasive scan called FibroScan, are linked to future serious liver problems like cirrhosis, liver cancer, o…
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Veterans study aims to boost colon and liver cancer screening
Knowledge-focused By invitation onlyThis study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can tracking hospital care for liver patients reduce repeat admissions?
Knowledge-focused OngoingThis study follows about 400 adults with liver cirrhosis admitted to internal medicine wards across Italy. Researchers will track how doctors manage hepatic encephalopathy—a brain complication of liver disease—during hospitalization and after discharge. The goal is to identify pr…
Sponsor: Fadoi Foundation, Italy • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Hidden costs of caregiving: new study tracks financial toxicity in cirrhosis families
Knowledge-focused OngoingThis observational study looks at the financial and social challenges faced by informal caregivers of people with cirrhosis. Researchers will measure out-of-pocket costs, lost work time, and financial distress using surveys. The goal is to understand how these burdens affect care…
Sponsor: University of Michigan • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Blood markers could transform liver cancer surveillance
Knowledge-focused OngoingThis study follows people with liver cancer who are scheduled for surgery, measuring tiny molecules called microRNAs in their blood before and after the operation. The goal is to find patterns that could signal whether the cancer has come back. Researchers will also look at gut b…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Blood test and AI could spot liver cancer early, saving lives
Knowledge-focused OngoingThis study follows 2,002 people at high risk for liver cancer to find better ways to detect it early. Researchers are testing a panel of blood-based miRNA markers, gut microbiome changes, and MRI-based AI algorithms to predict who develops the disease. The goal is to improve on c…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
Blood type no barrier? study tests liver transplant success across ABO barriers
Knowledge-focused By invitation onlyThis study looks back at 371 adults who received a living donor liver transplant for hepatocellular carcinoma (a type of liver cancer) to see whether receiving a liver from a donor with an incompatible blood type affects long-term survival or cancer recurrence. Researchers compar…
Sponsor: Seoung Hoon Kim • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Draining the bile duct: does it improve daily life for cancer patients?
Knowledge-focused OngoingThis study tracks quality of life in 118 people with cancer who have a blocked bile duct and undergo a drainage procedure. Participants fill out a questionnaire before the procedure and again at 4 weeks, 12 weeks, and 6 months after. The goal is to see whether a drainage catheter…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Liver cancer patients: which drug works best after immunotherapy?
Knowledge-focused OngoingThis observational study follows 300 adults with advanced liver cancer that cannot be removed by surgery. All participants have already received a first-line immunotherapy combination (like atezolizumab plus bevacizumab). Researchers will collect data from routine care to see how…
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Scientists hunt for clues in body fluids to predict liver failure outcomes
Knowledge-focused OngoingThis study aims to find biological markers in blood, urine, stool, and breath that can predict how patients with acute liver injury or failure will fare. Researchers will collect samples daily for up to seven days from 200 participants, and a small group will also undergo MRI sca…
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
10-Year hepatitis study aims to unlock secrets of liver disease
Knowledge-focused OngoingThis study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Massive korean study maps the overlap of heart, kidney, and metabolic diseases
Knowledge-focused By invitation onlyThis study examines health data from about 800,000 Korean adults to see how often conditions like obesity, type 2 diabetes, heart disease, chronic kidney disease, and fatty liver occur together. Researchers will analyze national survey and insurance records from 2013 to 2023. No …
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Scientists probe immune cell exhaustion in hepatitis b
Knowledge-focused OngoingThis study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive UK study tracks cancer after organ transplants
Knowledge-focused OngoingThis study looks at why people who have had an organ transplant are more likely to get cancer. Researchers will combine existing health records from over 85,000 transplant patients in England to track cancer cases and deaths. The goal is to better understand risks and improve car…
Sponsor: University of Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Fatty liver study pulled before it began
Knowledge-focused CancelledThis study was designed to look at how tiny energy-producing parts of cells (mitochondria) in the liver might be linked to fatty liver disease in people with obesity who were scheduled for weight-loss surgery. Researchers planned to take small liver samples during surgery to stud…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Simple blood test may spot hidden liver trouble in colitis patients
Knowledge-focused By invitation onlyThis study looks at whether two blood markers, zonulin and LBP, can help detect liver damage in people with both ulcerative colitis (UC) and fatty liver disease. Researchers will measure these markers and use a special ultrasound to check liver stiffness in 100 adults with UC who…
Sponsor: University Hospital Dubrava • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hepatitis b breakthrough? study checks if bepirovirsen response lasts
Knowledge-focused OngoingThis study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Egyptian study pits two liver cancer drug combos Head-to-Head
Knowledge-focused OngoingThis study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they …
Sponsor: Sohag Oncology Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Ultrasound for all: 9,000-Patient trial tests quicker hospital stays
Knowledge-focused OngoingThis study looks at whether using a simple bedside ultrasound exam on all hospitalized patients can shorten their hospital stay. Researchers will check the heart, kidneys, liver, and lungs for common problems. The goal is to see if this routine check helps doctors make faster dec…
Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Liver transplant study tests best way to manage fluids during surgery
Knowledge-focused OngoingThis pilot study compares two approaches to giving fluids during liver transplant surgery: a restrictive strategy that removes some blood early and returns it later, versus a liberal strategy that keeps blood flow high. The goal is to see if a larger study is possible by checking…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
COVID-19's hidden toll on liver cancer patients revealed
Knowledge-focused OngoingThis study looks at how COVID-19 impacts people with hepatocellular carcinoma, a type of liver cancer. Researchers will track infection rates and see how the virus affects liver function, cancer treatment, and overall health. About 23 participants from a French national liver can…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can the liver heal itself? new study tracks unexpected recovery in cirrhosis patients
Knowledge-focused OngoingThis study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…
Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a smartwatch help manage a rare liver disease? stanford study investigates
Knowledge-focused By invitation onlyThis study at Stanford University is testing whether wearable devices like smartwatches can help measure fatigue, sleep, and daily activity in people with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will compare data from the wearables with patient que…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Pandemic's hidden toll: frailty rises in liver transplant hopefuls
Knowledge-focused OngoingThis study examines whether the COVID-19 pandemic increased frailty and muscle loss (sarcopenia) in people waiting for a liver transplant. Researchers will compare data from 208 patients assessed before and during the pandemic. The goal is to understand how the pandemic affected …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
New screening tool aims to catch hidden need for palliative care in hospitals
Knowledge-focused OngoingThis study tests a questionnaire called NECPAL to see if it can spot patients with serious long-term illnesses like cancer, heart failure, or kidney disease who might benefit from palliative care. Researchers will check 200 adults in the hospital or day clinic to see how many are…
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Frailty check could predict chemo danger for seniors
Knowledge-focused By invitation onlyThis study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…
Sponsor: Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Scientists track rare liver diseases in kids to unlock clues
Knowledge-focused PausedThis study follows up to 90 children and young adults with mitochondrial liver diseases to learn how these conditions progress over time. Researchers will collect medical data and samples to better understand the diseases and find markers that predict outcomes. The goal is to imp…
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study tracks blood sugar in liver disease patients on common drug
Knowledge-focused OngoingThis study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Major study on rare childhood liver diseases halted
Knowledge-focused PausedThis study followed children and young adults with genetic liver diseases that cause bile buildup. The goal was to track how these diseases progress over time, including the need for liver transplants or other complications. No treatments were tested; the aim was simply to learn …
Sponsor: Arbor Research Collaborative for Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Veteran peers lead fight against opioid overdose
Knowledge-focused OngoingThis study tests a program where veteran peer workers provide education, healthcare navigation, and social support to 150 veterans with opioid use disorder who are not connected to VA healthcare. The goal is to reduce risky behaviors related to overdose and HIV/HCV infection. Res…
Sponsor: New York University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
Knowledge-focused By invitation onlyThis study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver …
Sponsor: Université de Montréal • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Can a special PET scan unlock a new way to treat Hard-to-Treat upper GI cancers?
Knowledge-focused OngoingThis study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…
Phase 2 • Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Kidney function may affect hepatitis b drug levels
Knowledge-focused OngoingThis study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
One shot enough? thai kids' hepatitis a immunity tested years later
Knowledge-focused OngoingThis study follows 60 healthy Thai children and teens who received a single dose of a live-attenuated hepatitis A vaccine about a year ago. Researchers want to see how many still have protective antibodies and at what levels. The goal is to understand long-term immunity and help …
Sponsor: Chiang Mai University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Keyhole vs open surgery: which is better for rare pancreatic cancer?
Knowledge-focused By invitation onlyThis study compares two surgical techniques—laparoscopic (keyhole) and open surgery—for treating a rare cancer near the pancreas called nonpancreatic periampullary adenocarcinoma. Researchers will track how long patients stay in the hospital after surgery, as well as survival rat…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Can scans tell who needs surgery after liver tumor shrinks?
Knowledge-focused OngoingThis study looks back at 500 people with liver cancer that could not be removed at first. After a mix of treatments (TACE, lenvatinib, and an immunotherapy drug), their tumors shrank enough to consider surgery. Researchers want to see if using scans and patient data can help deci…
Sponsor: First Affiliated Hospital, Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Porphyria biomarker hunt could transform patient monitoring
Knowledge-focused OngoingThis study aims to find new biological markers (biomarkers) that can show how active acute porphyria is in the body and how well treatments are working. Researchers will study 50 people with confirmed acute porphyria to measure gene activity related to heme production and stress …
Sponsor: The University of Texas Medical Branch, Galveston • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New registry to monitor hepatitis b vaccine safety in pregnancy
Knowledge-focused CancelledThis study was designed to collect information on pregnancy and baby outcomes in women who received the PREHEVBRIO hepatitis B vaccine around the time of conception or during pregnancy. The goal was to watch for any safety concerns, such as miscarriage or birth defects. However, …
Sponsor: VBI Vaccines Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Amino acid infusion study aims to unlock fatty liver secrets
Knowledge-focused OngoingThis study looks at how amino acids trigger the liver to release hormones in healthy people and those with non-alcoholic fatty liver disease. Researchers will give amino acid infusions with or without a drug that blocks natural hormone production. By comparing the results, they h…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Tiny sensors could revolutionize jaundice treatment for newborns
Knowledge-focused OngoingThis study tests a new wireless sensor that continuously measures the light dose babies receive during phototherapy for jaundice. Currently, doctors check light levels only once a day with a handheld device, which can be inaccurate. The sensor aims to provide real-time data to en…
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Liver cirrhosis study looks at cholesterol marker levels
Knowledge-focused PausedThis study measures levels of a substance called 4beta-hydroxycholesterol in the blood of people with liver cirrhosis. It compares these levels to those in people with pneumonia, Crohn's disease, or ulcerative colitis. The goal is to understand how cirrhosis and certain medicatio…
Sponsor: University of Oulu • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Personalized blood test aims to track stomach and colon cancer spread
Knowledge-focused PausedThis study is for people with gastrointestinal cancer that has spread to the lining of the abdomen. Researchers will collect tumor tissue and blood samples to create a custom blood test that looks for cancer DNA. The goal is to see if this test can help doctors monitor the cancer…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Prison hepatitis c study pulled before it began
Knowledge-focused CancelledThis study planned to see if faster testing and treatment for hepatitis C could be given to inmates right when they enter prison. The goal was to start medication sooner to reduce the spread of the virus. However, the study was withdrawn and no one took part.
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
One-stop screening clinic aims to catch hidden diabetes complications early
Knowledge-focused OngoingThis study is testing a new type of clinic that screens people with prediabetes and type 2 diabetes for several hidden health problems at the same time, including fatty liver disease, sleep apnea, and heart failure. The goal is to see how common these undiagnosed conditions are a…
Sponsor: University of Liverpool • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
240 cirrhosis patients studied to uncover hidden clot risks
Knowledge-focused OngoingThis study looks at 240 adults with liver cirrhosis to learn more about a common complication called portal vein thrombosis (a blood clot in the liver's main vein). Researchers will use ultrasound and CT scans to find clots and track their patterns. The goal is to identify which …
Sponsor: Elham Ahmed Hassan • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New study aims to detect liver damage without needles
Knowledge-focused OngoingThis study looks at whether simple blood tests and special scans can detect liver scarring in people with urea cycle disorders. Researchers will enroll 62 participants across five U.S. centers. The goal is to find noninvasive ways to monitor liver health, avoiding the need for li…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Gut bacteria may forecast surgery risks in pancreatic cancer patients
Knowledge-focused By invitation onlyThis study is collecting saliva, stool, blood, bile, and tumor samples from 200 people undergoing surgery for pancreatic or related cancers. Researchers want to see if the types of bacteria in these samples can help predict who will have complications after surgery and how the ca…
Sponsor: St. Antonius Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Early warning probe could save lives after pancreatic surgery
Knowledge-focused OngoingThis study tests a new monitoring method for patients who have had pancreatic surgery. After surgery, a thin probe is placed near the surgical connection to measure chemicals that may signal a leak before symptoms appear. Half of the 201 participants will receive this monitoring …
Sponsor: Oslo University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New MRI scan could predict liver cancer in NASH patients
Knowledge-focused OngoingThis study tests a new, longer MRI scan that measures liver stiffness and viscosity to see if it can identify NASH patients at higher risk for liver cancer. About 35 adults with NASH and early-stage liver scarring will participate. The goal is to improve early detection, not to t…
Sponsor: Natalie Torok • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a computer predict liver cancer before it strikes?
Knowledge-focused OngoingThis study checks if a computer model called LIRIC can accurately predict who will develop liver cancer using electronic health records. Researchers will track 6 million adults aged 40 and older without a history of liver cancer to see how well the model works. The goal is to imp…
Sponsor: Beth Israel Deaconess Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a new model forecast liver failure survival?
Knowledge-focused OngoingThis study looks at 2000 patients with acute-on-chronic liver failure caused by hepatitis B. Researchers will collect blood samples and medical data to build a model that predicts survival and complications at different time points. The goal is to give doctors a better way to est…
Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Liver disease growth study cancelled before it began
Knowledge-focused CancelledThis study planned to test a growth factor medicine (Increlex) in children aged 4-18 with chronic liver disease and short stature. The goal was to see if it could improve growth and quality of life. However, the study was withdrawn before any participants were enrolled, so no res…
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Simple ultrasound could spot liver trouble in heart kids
Knowledge-focused OngoingThis study follows 50 children with single-ventricle heart disease who have had the Fontan operation. Researchers use a special ultrasound to measure liver stiffness, which may indicate congestion and predict future complications like liver disease. The goal is to find a noninvas…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
100,000 families join landmark study on parental exposures and child health
Knowledge-focused OngoingThis study follows 100,000 Chinese families from before pregnancy through the child's teenage years. Researchers collect health data, biospecimens, and environmental information to understand how parents' exposures affect pregnancy outcomes and child development. The goal is to f…
Sponsor: National Research Institute for Family Planning, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a dental visit help liver patients?
Knowledge-focused OngoingThis study looks at whether offering dental exams and cleanings to people with cirrhosis can improve their oral health and overall well-being. Researchers will also ask participants about barriers to getting dental care. About 100 adults with confirmed cirrhosis will take part, a…
Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Fatty liver study pulled before it began: new imaging test never tested
Knowledge-focused CancelledThis pilot study was designed to see if a special MRI technique called field-cycling imaging could tell the difference between simple fatty liver and more serious liver scarring (fibrosis) in adults with non-alcoholic fatty liver disease (NAFLD). The goal was to find a non-invasi…
Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Major study aims to spare patients painful liver biopsies
Knowledge-focused By invitation onlyThis study follows 1,689 adults with fatty liver disease (MASLD) or MASLD with increased alcohol intake (MetALD) to see if non-invasive tests like MRI and Fibroscan can accurately track disease progression. The goal is to reduce the need for liver biopsies in future research and …
Sponsor: HRI-MAIL-NIT • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Hormone clues in cirrhosis and low blood pressure study withdrawn
Knowledge-focused CancelledThis study was designed to measure estrogen and testosterone levels in men with liver cirrhosis who also have low blood pressure, compared to those with cirrhosis but normal blood pressure. The goal was to understand why low blood pressure occurs in cirrhosis. However, the study …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Liver tumor treatment study halted before it began
Knowledge-focused CancelledThis study aimed to review past cases of a treatment called radioembolization (using tiny radiation beads) for liver tumors, including a rare type of bile duct cancer. The goal was to understand how well it works and what risks it carries. However, the study was withdrawn before …
Sponsor: Methodist Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Tumor DNA study aims to unlock secrets of drug resistance
Knowledge-focused OngoingThis study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Stomach ultrasound could spot liver trouble early
Knowledge-focused OngoingThis study looks at whether a new ultrasound technique done through the stomach (endoscopic ultrasound elastography) can better predict serious liver problems in people with chronic liver disease. Researchers will measure liver and spleen stiffness in 50 patients and compare resu…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Researchers watch and learn: liver transplant outcomes for cancer patients
Knowledge-focused OngoingThis study is a registry that follows 1,000 adults with liver cancer who receive a liver transplant. Researchers will track how long patients live without their cancer coming back and overall survival. The goal is to learn more about outcomes and what predicts recurrence, not to …
Sponsor: Federico Aucejo • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Liver patients face hidden fungal threat – new study seeks answers
Knowledge-focused OngoingThis study looks at why people with severe liver disease who are in the intensive care unit (ICU) are at risk for a dangerous fungal lung infection called invasive pulmonary aspergillosis. Researchers will study 450 patients to find better ways to predict, diagnose, and treat thi…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Massive pancreatic surgery registry launches to improve patient care
Knowledge-focused OngoingThis registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Cheaper brain monitoring method tested in liver transplants
Knowledge-focused OngoingThis study compares two non-invasive methods for monitoring brain blood flow during liver transplant surgery: carotid Doppler ultrasound and near-infrared spectroscopy (NIRS). The goal is to see if the simpler, cheaper ultrasound can replace the more expensive NIRS. The study inv…
Sponsor: Inonu University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Hope for hepatitis delta patients: study seeks to end lifelong treatment
Knowledge-focused OngoingThis study looks at whether people with chronic hepatitis delta who have been on bulevirtide for at least 48 weeks and have very low virus levels can safely stop treatment. Researchers will monitor 20 participants for 48 weeks after stopping to find biological markers that predic…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Fatty liver and psoriasis study pulled before it started
Knowledge-focused CancelledThis study aimed to understand the link between non-alcoholic fatty liver disease (NAFLD) and psoriatic disease (psoriasis and psoriatic arthritis) in overweight adults. Researchers planned to use the drug guselkumab (Tremfya) to see if it improved both conditions. However, the t…
Sponsor: University of California, San Diego • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New scan could help spare healthy liver during cancer radiation
Knowledge-focused OngoingThis pilot study tests a special SPECT imaging scan called hepatobiliary scintigraphy to measure how radiotherapy changes liver function. Twenty adults with liver cancer will get the scan before and after radiation. The goal is to see if this method can show which parts of the li…
Sponsor: Royal North Shore Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Electric shocks + chemo: new hope for liver tumors?
Knowledge-focused OngoingThis study is a registry that collects information on how well electrochemotherapy (ECT) works for people with liver cancer. ECT uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The study will follow 250 adults with primary or secondary l…
Sponsor: Cardiovascular and Interventional Radiological Society of Europe • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New decision aid aims to boost liver cancer screening in veterans
Knowledge-focused By invitation onlyThis study tests a new decision aid tool (OASIS) that helps VA hospitals choose the best strategies to improve screening for liver cancer in patients with cirrhosis. Over 8,000 veterans and clinicians at multiple VA medical centers will participate. The goal is to see if the tool…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Scientists observe liver disease progression in 24 patients
Knowledge-focused OngoingThis study follows 24 adults with liver cirrhosis who recently had a sudden worsening (decompensation) requiring hospital care. Researchers will track their health over time, including lab results and major events like death or liver transplant. The goal is to better understand t…
Sponsor: Resolution Therapeutics Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Study probes how poverty and support shape child transplant success
Knowledge-focused OngoingThis study looks at how social factors like income, education, and community support impact recovery in 500 children after liver transplant. Researchers will survey caregivers and interview families to understand barriers to good outcomes. The goal is to find ways to better integ…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Simple nudge: mailed reminders and navigators may catch liver cancer earlier
Knowledge-focused OngoingThis study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
1,200-Patient study aims to predict liver failure risks
Knowledge-focused OngoingThis observational study follows 1,222 adults with liver cirrhosis to understand why some develop serious complications like fluid buildup or bleeding. Participants have check-ups every six months, including questionnaires, physical exams, and imaging. The goal is to build better…
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Rare bile duct cysts: how often do they turn into cancer?
Knowledge-focused By invitation onlyThis study reviews medical records of 300 people diagnosed with choledochal cysts (bile duct cysts) between 2000 and 2020 in Western hospitals. The goal is to find out how often these cysts lead to bile duct cancer and what factors increase that risk. By analyzing symptoms, treat…
Sponsor: María Teresa Moreno Asencio • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
120,000-Person study hopes to crack the code of chronic illness
Knowledge-focused PausedThis observational study plans to enroll 120,000 people with various chronic diseases like pancreatitis, diabetes, and arthritis. Researchers will collect blood samples and health data to study how genetics and lifestyle affect disease progression. The goal is to find common dise…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Diabetes and liver danger: new study follows 317 patients to uncover hidden risks
Knowledge-focused By invitation onlyThis study follows 317 adults with type 2 diabetes who were first examined between 2019 and 2023. Researchers will repeat advanced liver scans, blood tests, and body composition measurements to see how liver fat and scarring change over time. The goal is to find out who is most a…
Sponsor: Linkoeping University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New imaging study aims to spare patients painful liver biopsies
Knowledge-focused OngoingThis study tests whether special PET scans can accurately measure fat, swelling, and scarring in the liver of people with non-alcoholic fatty liver disease (NAFLD). Researchers will compare scan results with standard liver biopsies from 120 adults. If successful, this could lead …
Sponsor: University of California, Davis • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Hidden liver risk in diabetes patients revealed
Knowledge-focused OngoingThis study aims to find out how many people with type 2 diabetes also have non-alcoholic fatty liver disease (NAFLD). Researchers will use a special ultrasound scan (FibroScan) to check the liver health of 385 adults with type 2 diabetes. The study does not test any new treatment…
Sponsor: Ziekenhuis Oost-Limburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Can an MRI spot hidden dangers in type 2 diabetes?
Knowledge-focused OngoingThis study follows 135 adults with type 2 diabetes over several years, using special MRI scans to check their liver, kidneys, and heart. The goal is to find out which patients are more likely to develop serious complications. No new treatments are being tested—just a better way t…
Sponsor: Perspectum • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
New diabetes drug tested in patients with liver problems
Knowledge-focused OngoingThis study looks at how a single dose of the experimental drug GZR4 injection behaves in people with mild, moderate, or severe liver impairment compared to those with normal liver function. The goal is to understand the drug's safety and how the body processes it. 36 adults with …
Phase 1 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Can blood tests predict liver Cancer's return?
Knowledge-focused OngoingThis study is collecting blood and tissue samples from 360 people with early-stage liver cancer who have had surgery to remove their tumors. Researchers want to find biological markers that could predict if the cancer will come back. The goal is to better understand the immune sy…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Rare disease study pulled before starting: scientists sought clues in cell stress
Knowledge-focused CancelledThis study was planned to learn how certain rare genetic mutations disrupt protein production and cause severe diseases affecting the lungs, liver, brain, and digestion. Researchers would have used cells from patients to measure protein levels and stress responses. However, the s…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Tiny study hopes antiviral drug eases dangerous liver pressure
Knowledge-focused OngoingThis observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:20 UTC
-
New study aims to replace painful liver biopsies with ultrasound and blood tests
Knowledge-focused OngoingThis study follows 163 obese patients undergoing bariatric surgery to see if non-invasive tools like ultrasound and blood markers can accurately diagnose fatty liver disease (MASLD) and predict diabetes remission. Researchers will compare these tests to liver biopsy results befor…
Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:57 UTC